OBM Neurobiology

ISSN 2573-4407
Free Publication in 2018

Current Issue: 2018  Archive: 2017 

Contribution of PET Imaging to Clinical Management of Gliomas

Wolf-Dieter Heiss *

  1. Max Planck Institute for Metabolism Research, Gleueler Str. 50, D-50931, Cologne, Germany

*   Correspondence: Wolf-Dieter Heiss

Received: July 2, 2018 | Accepted: September 5, 2018 | Published: September 20, 2018

OBM Neurobiology 2018, Volume 2, Issue 3, doi:10.21926/obm.neurobiol.1803011

Academic Editors: Antonio Meola

Special Issue: Tumors of the Central Nervous System

Recommended citation: Heiss WD. Contribution of PET Imaging to Clinical Management of Gliomas. OBM Neurobiology 2018;2(3):011; doi:10.21926/obm.neurobiol.1803011.

© 2018 by the authors. This is an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.


The optimal treatment of craniopharyngiomas (CPs) represents a neurosurgical challenge, the major reason being their close relationship with the hypothalamus and the third ventricle (3V) boundaries. Nevertheless, CPs are generally defined as “suprasellar” lesions, an inexplicit and frequently defective term. Despite being heterogeneous lesions, CPs are actually characterized by repeating pathological patterns which depend on their point of origin along the pituitary-hypothalamic axis. Surgical plan in tailoring the best treatment strategy needs to take in consideration some critical aspects, including the understanding of the accurate CP-hypothalamus relation. Without firm consensus and proposed guidelines for the appropriated management of CPs, radical removal and conservative resection remain the two opposing therapeutic strategies. However, an increasing leading of opinions stress out these two strategies should be replaced by a tailored plan to pursue the maximal tumor resection while minimizing the likelihood of hypothalamic injury in each case. Based on the accurate definition of the CP-third ventricle floor relationship, our topographical scheme has been proven useful to predict the degree of hypothalamic distortion and adherence to the tumor. This is an essential information to predict the surgical risk associated with radical tumor removal. Apart from the sellar-suprasellar category of CPs which is formed by tumors growing below a non-distorted third ventricle floor (TVF), four major CP topographies can be considered: i) suprasellar-pseudointraventricular CPs, that grow below an intact but upward displaced TVF; ii) suprasellar-secondary intraventricular CPs, which originate below the TVF but break through it and invade the 3V; iii) not-strictly intraventricular or infundibulo-tuberal CPs, which originate within the TVF itself and predominantly expand into the 3V; and iv) strictly intraventricular CPs that wholly develop within the 3V, above an intact TVF. The most extensive and strongest CP-hypothalamic adhesions occur in the secondary intraventricular and infundibulo-tuberal categories. A hypothalamic position around the middle portion of the tumor, an amputated pituitary stalk and an elliptical tumor shape on preoperative MRI are reliable signs to predict a high-risk CP adherence severity level. In the cases with these radiological signs a limited removal is strongly advocated.


Craniopharyngioma; topography; hypothalamus; third ventricle; adherence; adhesion; infundibulo-tuberal; treatment; trans-lamina terminalis approach; endoscopic transsphenoidal approach

1. Introduction

Defined by the World Health Organization as “benign, partly cystic epithelial tumours”, craniopharyngiomas (CPs) are widely regarded as rare brain tumours and considered as challenging intracranial tumours, despite their histological classification. Such a major neurosurgical challenge is due to their intimate relation with the hypothalamus and third ventricle (3V) boundaries. Nevertheless, analysis of the underlying CP pathological and topographical features related to this type of tumors is scarce in medical literature. On the one hand, most studies assume the inaccurate concept of a primary suprasellar position for most CPs, even though this heterogeneous type of lesion may develop at any point along the pituitary-hypothalamus axis, from the sella turcica to the 3V. Moreover, it should be kept in mind that almost half of CPs develop at the level of the third ventricle floor (TVF), within the infundibulum and/or the tuber cinereum, regions including the vital hypothalamic nuclei [1,2,3,4,5]. On the other hand, the extreme heterogeneous CP morphology has definitely contributed to thwart a clear identification of the topographical and pathological CP features which allow the definition of those subgroups of cases associating a high surgical risk. The thorough assessment of 3,705 documents relating to CPs, including books, individual well-reported cases, surgical case series and historical case series such as Cushing’s series recorded in the Brain Tumor Registry (n=124) or the pathological series housed in the Narrenturm, Vienna (n=25), has allowed us to study over 5,000 CPs, including brain specimens from non-operated tumors and surgically treated lesions. We have been able to affirm that CPs, despite representing a morphologically heterogeneous type of tumor, are characterized by repeating topographical and pathological patterns that can be differentiated in anatomical studies [4,6,7]. As hypothalamic dysfunction is the major cause of death and serious morbidity following CP surgery, an accurate preoperative definition of the specific anatomical CP-hypothalamus relationship is essential to plan the most appropriate surgical approach and degree of excision for each case. Regarding this issue, we have recently showed that conventional preoperative MRI studies can reliably predict the accurate CP topography and CP-hypothalamus adhesion pattern to be found in the surgical procedure [8,9]. The aim of this review is to present a critical overview of gathered knowledge on topographical and pathological concepts regarding to CPs that should be considered when planning surgical treatment of these complex lesions.

2. Craniopharyngiomas: A Heterogeneous Group of Epithelial Lesions Developed along the Hypothalamic-Pituitary Axis

2.1 Pathological Definition of Craniopharyngiomas: Historical Background

The morphological and pathological heterogeneity of CPs has notably contributed to the difficulty in classifying these lesions throughout history. In the Nineteenth Century, a vast list of ambiguous terms such as medullary sarcoma, carcinoma of the pituitary gland, ependymal papilloma, cystosarcoma, cholesteatoma, and teratoma, were used to refer to lesions growing in the vicinity of the suprasellar area and showing gross pathological features typical of what we currently known as CPs today [10,11,12]. This extremely varied terminology has generated a lot of confusion. The first comprehensive classification of tumors related to the pituitary gland was presented in 1893 by Sir Rupert William Boyce (1863-1911), an assistant professor of Pathology at University College of London [13]. Based on the systematic study of 3,000 brain autopsies, he was able to differentiate the category of “pituitary strumas” or glandular neoplasms, from the remaining hypophyseal or infundibular tumors, such as granulomas, teratomas and carcinomas. Boyce used the term “pituitary cyst” for lesions resembling CPs owing to his erroneous assumption that these tumors developed from an excess of pituitary secretion [13].

The pathological entity of CPs was first systematically defined a decade later, in 1904, by the Austrian pathologist Jakob Erdheim (1874-1937) [14]. The confluence of several fortunate circumstances contributed to Erdheim’s definition of CPs as a separate tumor entity. Carl Benda had recently introduced new staining methods for pituitary gland cells that allowed the differentiation of pituitary “strumas” (adenomas) [15]. In addition, Erdheim had shown a particular interest in the pathological alterations involving the pituitary gland since the beginning of his career and was able to study in detail the collection of old brain specimens with pituitary tumors gathered at the Pathological Anatomical Museum in Vienna, stored at the Narrenturm (the former hospital for insane patients in Vienna) [16,17]. The methodical study of a few sets of cystic lesions developed at the infundibulum in these brain specimens eventually led him to define the new pathological category of “hypophysengangsgeschwülste” (hypophyseal duct tumor), a term under which he grouped the heterogeneous epithelial growths developing either from the pituitary stalk or from the infundibulum (presumably from the pars tuberalis, the thin layer of glandular adenohypophyseal tissue wrapping around the pituitary stalk and infundibulum) [14,16]. Erdheim showed great originality in relating the presence of squamous epithelial cell nests within the pars tuberalis, with the embryological development of the pituitary gland and growth of CPs [14]. With brilliant insight, he proposed that these tumors could originate from epithelial cell remnants of Rathke’s pouch (the embryonic primordium of the pituitary gland) or, more accurately, from non-involuted remnants of the craniopharyngeal duct (Rathke’s pouch’s path of migration connecting the embryo’s mouth and TVF at the earliest stages of pituitary gland development) that was included within the pars tuberalis [14,16]. Although CP pathogenesis is still controversial, recent molecular studies support Erdheim’s embryological theory that CPs are thought to originate from displaced embryonic stem cells of the primitive stomodeum located along the pituitary-hypothalamic axis [17,18]. In his monumental masterpiece, Erdheim not only defined the CP entity but also characterized the two major histological variants with distinct morphological and molecular features currently considered in the WHO classification: adamantinous (ACP) and the squamous-papillary (PCP) types, for which he suggested a common embryonic pathogenesis [20,21]: The adamantinous type consisted of lesions similar to adamantinomas or odontogenic jaw tumors, characterized by strands of a multistratified squamous epithelium with peripheral palisading of nuclei that enclosed sheets of “stellate reticulum” and cysts filled with cell debris and cholesterol particles. The squamous-papillary type included lesions similar to papillomas of the oral mucosa, typically formed of a unilocular cyst, whose inner wall was lined with a squamous epithelium forming wart-like or cauliflower-like excrescences [16]. Finally, Erdheim also pionnered the relationship between the damage of the of the infundibulo-tuberal area by CPs and the presence of obesity observed in many patients [22,23,24].

Three decades later, in 1929, the founding father of scientific neurosurgery, Harvey Cushing (1869-1939), introduced the easy-to-remember term “craniopharyngioma” [25]. Despite these lesions not originating from the pharynx but rather from an embryo’s primitive buccal cells migrating with Rathke’s pouch/craniopharyngeal duct, the term “craniopharyngioma” eventually triumphed over Erdheim’s more accurate term of “hypophyseal duct tumors” [12,25]. The heterogeneity of CPs regarding their location and their varied extent of adhesion to the surrounding brain structures, commonly led to either failed craniotomies and/or to a high rate of death or life-ruining hypothalamic symptoms, that puzzled Cushing throughout his career. For this reason, he defined CPs as the “most baffling problem which confronts the neurosurgeon” [26]. One century later, CPs remain one of the most formidable and challenging intracranial tumors faced by practitioners.

2.2 Craniopharyngioma: Not a Suprasellar but a True Hypothalamic Tumor

CPs have been classically claimed to represent a suprasellar, extra-axial type of epithelial lesion. Unfortunately, the term “suprasellar” remains invariably linked to the concept of CPs, and it still dominates the neurosurgical and neuroradiological literature on these tumors [20,27,28]. The widespread use of the term “suprasellar” for CPs dates back to the early 20th Century, when the identification of dense shadows above the sella turcica represented the major radiological sign to ascertain the preoperative diagnosis of these lesions [25,26]. The problem posed by this imprecise term is that it may cause an inaccurate topographical definition of the tumor, consequently leading to an incorrect surgical decision, due to the fact that the term suprasellar misses the fundamental point: “the tumor involvement of the vital hypothalamus”. The systematic study of anatomical CP relationships in both surgical and pathological cases published in the literature has proved that this tumor type predominantly involves the 3V and encroaches upon the hypothalamus [3,6,7].

Percival S. Bailey (1892-1973), one of Cushing’s most talented assistants, had a particular interest in neuropathology and was the first author to define CPs as true hypothalamic tumors [29]. The methodical study of Cushing’s vast collection of CP specimens, in addition to Bailey’s interest in hypothalamus physiology, led the latter to notice that most CPs developed within the hypothalamic region and predominantly extended into the 3V [10,29]. Bailey also recognized that diabetes insipidus, adiposogenital dystrophy (Fröhlich’s syndrome) and hypersomnia were all typical symptoms in CP patients that revealed hypothalamic involvement by the tumor [29]. Comprehension of the pathological and physiological close relation between CPs and the hypothalamus was crucial for further developing surgical strategies aimed at minimizing the likelihood of devastating hypothalamic injury associated with CP surgery. In 1938, Norman M. Dott (1897-1973), another Cushing fellow who worked with Bailey in Boston, reported the first account of the successful surgical treatment of CPs centered at the hypothalamus [30,31]. Dott proposed a novel strategy, including a two-stage approach (a subfrontal route followed by a transcortical-transventricular approach) to remove both the suprasellar and the intraventricular components of the tumor under direct view. He also warned about leaving untouched the basal portion of the tumor strongly adhered to the TVF in order to avoid undue injury to the adjacent hypothalamus [30].

The following generation of British neurosurgeons, headed by Douglas Northfield (1902-1976), contributed to emphasize the concept of a true hypothalamic, tuberal topography for a large number of CPs. Based on the ischemic/hemorrhagic lesions found within the hypothalamus in the autopsy of patients who died following surgical attempts at removal of CPs originated in the infundibulo-tuberal region, Northfield warned about the impossibility of resecting those lesions growing in the basal hypothalamus [32]. Recent studies focusing on the meningeal relationships between CPs and the pituitary-hypothalamic axis in a large series of tumors reported by Song Tao Qi et al. found that a subarachnoid-subpial position of the lesion within the TVF, without any intervening membranous layers between the tumor and the hypothalamus, occurred in 30% and 50% of pediatric and adult patients, respectively [5,33,34]. In light of the aforementioned information, the generalized and misleading term “suprasellar” should be abandoned and substituted by an accurate description of CP topography.

3. Topographical Classifications of Craniopharyngiomas

Currently there are numerous classification schemes for CP topography that have been proposed. Table 1 summarizes the major twenty-six topographical schemes published in the literature since this entity was defined in 1904 to the present. These series include a total of 2,480 CP cases. In most of them, surgical evidence represented the principal source of information [35,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58]. Only six classifications were based on the pathological evidence of the relationships between the tumor and adjacent intracranial structures identified on brain autopsy specimens [1,4,5,6,14,32,33,34,59,60,61,62]. Among these schemes, the one presented by Juraj Steno in 1985 deserves special attention because it is the first modern topographical classification based on the anatomopathological features of 30 brain specimens of non-operated CPs [1]. Stenos’ scheme takes into consideration the degree of TVF involvement by the lesion, classifying CP topography into three major types: i) purely extraventricular lesions developed in the sellar and/or suprasellar compartments outside the 3V; ii) extraventricular-intraventricular CPs that grow in both the suprasellar cistern and the 3V cavity, in which the TVF remnants are located around the mid-third of the tumor; and iii) purely intraventricular CPs wholly developed within the 3V above an intact TVF [1]. Shortly afterwards, Ivan S. Ciric published the only CP classification based on the embryological development of the leptomeningeal layers and the relative position of the epithelial remnants of Rathke pouch cells [63]. Ciric’s scheme included a depth axis from the outer meningeal layers to the inner nervous tissue and distinguished three groups of lesions: i) extrapial-intrarachnoid CPs, separated from the TVF tissue by the arachnoid and pia layers; ii) partially intrapial CPs, growing inside the nervous tissue of the TVF; and, iii) completely intrapial CPs, developing purely inside the 3V above an intact TVF. Finally, several topographical schemes are mainly based on MRI studies, including the two French classifications discussed below [64,65,66,67].

In the early 1990s, the neuroradiologist Charles Raybaud differentiated four major anatomic regions that could be occupied by the tumor: the sellar; suprasellar; infundibulo-tuberal; and third ventricle compartments. He observed that the majority of CPs primarily develop in the infundibulo-tuberal region, and his classification was the first MRI-scheme supporting the concept that CPs represent a type of lesion primarily involving hypothalamus [64], as had been previously found in the autopsy studies led by Erdheim and Steno [1,14]. More recently, Christian Sainte-Rose and Stephanie Puget introduced a topographical CP scheme based on the appearance of the hypothalamus on preoperative MRI scans, which also took into consideration patient outcome [66,67]. This scheme distinguished three major degrees of hypothalamic distortion caused by the tumor: i) grade 0, which corresponds to cases without hypothalamus distortion; ii) grade 1, included tumors causing hypothalamus displacement; and iii) grade 2, formed by tumors encroaching upon the hypothalamus, which cannot be identified on preoperative MRI [66,67]. Saint-Rose and Puget’s scheme, however, has the drawback of assuming that the 3V involvement depends on the progressive expansion of a tumor theoretically originated at the sellar/suprasellar region, without taking into consideration the multiplicity of CP locations along the pituitary-hypothalamic axis. Furthermore, the appearance of the TVF on preoperative MRIs cannot be used as a valid sign to reliably ascertain the anatomical integrity of this structure. For example, an unidentifiable TVF does not necessarily signify its anatomical disruption by the tumor. In a recent study analyzing the anatomical CP relationships for a series of 17 intraventricular CPs, it was found that 15% of the cases whose TVF could not be identified on preoperative MRIs actually corresponded to purely intraventricular CPs presenting a small pedicle attachment to the intact TVF, a low-risk adhesion type allowing a safe radical removal [5].

3.1 Topographical Craniopharyngioma Schemes: Anatomical Reference Axes Used

According to the anatomical axis considered for CP classification, four major types of topographical CP schemes can be distinguished (Table 1):

Topographical classifications considering one vertical axis. A total of 12 series considered the occupation of the compartments along the vertical sellar-3V axis (sellar, suprasellar, infundibulo-tuberal and 3V) as the main criterion for CP classification [14,32,41,42,43, 45,46,47,48,49,50,51,52,53,54,57,59,64,65,66,67]. The problem with many of these schemes is that they may lead to the erroneous idea that all CPs originate within the sella/suprasellar area and then progressively expand towards the 3V as they enlarge. Rather, different potential primary sites of CP development should be contemplated.

Table 1 Summary of the major topographical classifications of craniopharyngiomas

Author, year [Ref]

Number (children)

Classification model

Anatomical structure of reference

Major locations considered



Erdheim, 1904 [14]

28 (5) A



Infundibulum, Tuber cinereum, 3V

I: sellar-SS-3V (25%)

II: SS-pseudo-3V (18%)

III: infundibulo-tuberal 3V (42%)

IV: pure intraventricular (14%)

Northfield, 1957 & 1973 [32,59]

49 (23)

Surgical & Pathological



I: intrasellar (6%)

II: subtuberal (30%)

III: tuberal/3V (63%)

Rougerie 1962 & 1979 [35,36]

140 (92)



Sella, Chiasm

I: Intrasellar (11%)

II: intra-SS prechiasmatic (51%)

III: intra-SS retrochiasmatic (36%)

IV: giant (2%)

Pertuiset 1962 & 1975 [37,38]



Vertical & AP

Sella, Chiasm

I: intrasellar

IIa: SS-prechiasmatic (15%)

IIb: SS-subchiasmatic (50%)

IIc: SS-retrochiasmatic (35%)

IId: SS-pseudo-3V

III: intraventricular

Hoffman 1977, 1992 [39,40]

50 (17)



Sella, Chiasm

I: intrasellar (4%)

II: SS-prechiasmatic (25)

III: SS-retrochiasmatic 3V (46%)

Konovalov 1981, 1992 and 2013 [41,42,43]


198 (139)



Sella, TVF

I: endosellar-SS

II: SS-extraventricular

IIIa: SS-3V (30%)

IIIb: pure intraventricular (12%)

IV: giant

Steno 1985 [1]

30 (10) A


Vertical & Meningeal-brain depth*

Meningeal layers, 3V

I: intrasellar-SS (13%)

II: SS-extraventricular (13%)

III: intra and extraventricular (46%)

IV: intraventricular (26%)

Ciric 1987 [63]



Vertical & Meningeal-brain depth*

Meningeal layers, infundibulum

I: extrapial-extra-arachnoid

II: extrapial-extra/intra-arachnoid

III: extrapial-intra-arachnoid

IV: extrapial-intrapial

V: intrapial-intraventricular

Sweet 1988 [44]

43 (21)


Vertical & AP

Chiasm, 3V

I: intrasellar (3%)

II: SS-prechiasmaic

III: SS-subchiasmatic

IV: retrochiasmatic-3V (58%)

V: intraventricular

Raybaud 1991 [64]

23 (17)


Preop MRI


Sella, TVF

I: intrasellar-pre/retrochiasmatic (34%)

II: infundibulo-tuberal (43%)

III: strict intraventricular (8%)

IV: giant (13%)

Maira 1995, 2000, 2004 [45,46,47]


Surgical & preop MRI


Sella, 3V

I: intrasellar (12%)

II-intra-SS (40%)

III: SS (10%)

IV: SS-3V (30%)

V: pure intraventricular (8.5%)

Samii 1995 [48]

24 (10)



Sella, 3V

I: intrasellar

II: suprasellar-intracisternal

IIa: prechiasmatic

IIb: subchiasmatic

IIc: retrochiasmatic (40%)

III-IV: suprasellar-3V

De Vile 1996 [65]

75 (16)

Postop MRI



Grade O: intact TVF (29%)

Grade 1: infiltrated TVF (11%)

Grade 2: displaced TVF (19%)

Grades 3-4-5: breached (small-medium-whole) TVF (41%)

Yasargil 1996 [49]

162 (80)



Diaphragma sellae, 3V

I: intrasellar (7%)

II: intrasellar-SS (2%)

III: SS-extrasellar-3V (45%)

IV: intrasellar-extrasellar-3V (42%)

V: paraventricular (4%)

VI: pure intraventricular (5%)

Fahlbusch 1999 & Hofmann 2012 [50,51]

221 (40)

Surgical & Preop MRI


Sella, 3V

I: intrasellar (2%)

II: intrasellar-SS (35%)

III: SS (22%)

IV: SS-extra-intra3V (35%)

V: intraventricular (6%)

Zhang 2002, 2008 [68,69]

202 (202)

Surgical & Preop MRI

AP & Lateral

Pituitary stalk, Chiasm

I: intrasellar (2%)

II: SS-retrostalk (14%)

III: SS-junction stalk and chiasm-3V (67%)

IV: SS-prestalk-subchiasmatic (15%)

V: lateral to the pituitary stalk (4%)

Wang 2002, 2005 [60,61]

25 (25)

Surgical & Pathological

Vertical & AP

Diaphragma sellae

I: intrasellar (15%)

II: SS-subdiaphragmatic-prechiasmatic (56%)

III: SS-supradiaphragmatic-retrochiasmatic (32%)

IV: sub-supradiaphragmatic (12%)

V: giant

Pascual 2004, 2011, 2013 [4,6,62]

224 (63)

Surgical & Pathological & Preop MRI

Vertical & Meningeal-brain depth*


I: sellar/SS-Pseudo3V (14%)

II: sellar/SS-Secondary 3V (23%)

III: Not strict 3V or infundibulo-tuberal (40%)

IV: Strict 3V (23%)

Tomita 2005 [52]

54 (54)

Surgical & Preop MRI


Sella, 3V

I: intraellar (5%)

II: sellar-SS (37%)

III: sellar-3V (40%)

IV: intraventricular (16%)

Sainte-Rose 2005 & Puget 2007 [66,67]

103 (103)

Surgical & Preop MRI



Grade 0: Not distorted hypothalamus (21%)

Grade 1: Compressed hypothalamus (37%)

Grade 2: Invaded hypothalamus (42%)

Shi 2006 & 2008 [53,54]

309 (50)

Surgical & Preop MRI


Sella, 3V

I: superior or pure 3V (8%)

II: inferior-SS (44%)

III: inferior-SS-3V (32%)

IV: inferior-parasellar (7.5%)

V: inferior-intrasellar (1%)

Kassam 2008 [55]

16 (9)

Surgical (E-TS)

Vertical & AP

Infundibulum, 3V

I: preinfundibular

II: transinfundibular

IIIa: retroinfundibular-3V

IIIb: retroinfundibular-interpeduncular


IV: pure intraventricular

Qi 2011 & Pan 2011 [5,33,34]

195 (81)

Surgical & Preop MRI & Postop MRI & Pathological

Vertical & Meningeal-brain depth*

Meningeal layers, Infundibulum

I: intrasellar-infradiaphragmatic (43%)

II: extra-arachnoid-extra3V (5%)

III: intra-arachnoid-extra3V (7%)

IV: extra-intra3V (5%)

V: subarachnoid or infundibulotuberal (50-60%)

VI: intraventricular (8%)

VII: trasninfundibular-3V

Mortini 2011 [56]

112 (34)

Surgical & Preop MRI

Vertical & AP

Sella, 3V

I: intrasellar (4%)

II: intrasellar-SS (32%)

III: SS (36%)

IV: retrosellar (21%)

V: retrosellar-3V (6%)

Cavallo 2013 [57]

12 (1)

Surgical (E-TS) & Preop MRI


Pituitary stalk, Infundibulum

I: PS-infundibulum

II: infundibulum-3V

III: stalk-infundibulum-3V

Tang 2018 [58]


Surgical (E-TS)

Vertical & Lateral

Pituitary stalk

I: peripheral (72%)

Ia: hypothalamic-stalk (55%)

Ib: SS-stalk (21%)

Ic: intrasellar-stalk (24%)

II: central (28%)

AP: anteroposterior; Meningeal-brain depth*: depth axis from the outer meningeal layers to the inner nervous tissue; E-TS: endoscopic transsphenoidal route; TVF: third ventricle floor; SS: suprasellar; Preop MRI: preoperative Magnetic Resonance Imaging: Postop MRI: postoperative MRI; 3V: third ventricle.

Topographical classifications considering one horizontal or antero-posterior axis. Two classic surgically-based schemes used the optic chiasm to classify the position of CPs as this was the main anatomical structure seen through the frontotemporal or pterional approach [35, 36, 39, 40]. These schemes distinguished three major CP topographies: i) prechiasmatic CPs―for tumors originated below the chiasm which expand between both optic nerves; ii) subchiasmatic CPs―for the tumors displacing the optic nerves and chiasm upwards; and iii) retrochiasmatic CPs―for lesions hidden behind the optic chiasm and pushing this structure forward, most of them expanding within the 3V. The problem with the term “retrochiasmatic” is that it does not provide any information about the accurate relationship between the tumor and the 3V-hypothalamus in these schemes.

Topographical classifications considering two axes: one vertical or lateral and one horizontal. Five CP classifications are based on the vertical and antero-posterior axes [37, 38, 44, 55, 56, 60, 61], and two schemes consider the lateral position of the tumor relative to the pituitary stalk in addition to either an antero-posterior axis [68, 69] or a vertical axis [58]. For example, William H. Sweet (1910-2001), who advocated the pterional-trans-lamina terminalis route for CPs, proposed a scheme based on tumor position relative to the optic chiasm and 3V. Very recently, Amin K. Kassam [55] and Bin Tang [58], two experts in the endoscopic extended transsphenoidal approach, used the pituitary stalk and infundibulum as the structures of reference to define CP topography due to the fact that they are the first ones identified when using the transsphenoidal route. Specifically, Kassam’s scheme considers four major CP types [55]: i) preinfundibular CPs, or lesions located in front of the stalk-infundibulum complex, just behind the optic chiasm; ii) transinfundibular CPs, tumors expanding into the pituitary stalk itself; iii) retroinfundibular CPs, corresponding to those lesions growing behind the stalk-infundibulum complex which can expand either into the 3V cavity or towards the suprasellar-interpeduncular compartments; and iv) intraventricular CPs, situated above an intact pituitary stalk. The removal of this last type through an endonasal transsphenoidal route necessarily compels breaking through an anatomically intact TVF.

Topographical classifications considering two axes: one vertical and one depth axis through the leptomeningeal-brain tissue complex forming the TVF. Four studies classified the tumor location along the vertical pituitary-hypothalamic axis in addition to considering how deeply the tumor extended into the leptomeningeal layers and nervous tissue [1, 3-6, 33, 34, 62, 63, 70, 71]. Steno’s scheme was the first to highlight that the presence of an intervening meningeal layer between the tumor and the outer-pial aspect of the TVF in CPs developed beneath an intact TVF allowed a straightforward and safe removal of these tumors except in recurrent cases [1, 2]. A safe radical removal could be also achieved in purely intraventricular CPs in which the TVF was found to be anatomically intact below the lesions. On the contrary, he noticed that the highly prevalent group of CPs with an extra-intraventricular position, formed by lesions centered at the TVF, was characterized by direct contact between the tumor and the hypothalamus. The strong adhesions between these tumors and the surrounding TVF remnants explained the highest surgical risk of hypothalamic injury when attempting a radical removal of this CP topography [1]. The recent surgical classifications proposed by Pascual et al. and Qi et al. [4-6, 33, 34, 62] integrate the pathological concepts evidenced in Steno’s seminal study [1] with the embryological theory proposed by Ciric [63]: that those CPs developing within the neural tissue of the infundibulum/tuber cinereum are originated from Rathke’s pouch cell remnants coming into contact with the diencephalic vesicle floor before the pia mater is formed and covers the basal brain surface.

3.2 Topographical Craniopharyngioma Classification Based on the Assessment of the Third Ventricle Floor Status: Surgical Implications of Our Model

The most important aspect when planning CP surgery is to well understand the anatomical position of the hypothalamus relative to the tumor, with the aim of predicting the likelihood of achieving a safe resection. In this regard, in 2004, our group presented a comprehensive classification scheme for CPs based on the definition of the accurate anatomical relationships between the tumor and the TVF, the region containing hypothalamic nuclei. This anatomical area is essential for monitoring vital functions such as food intake, body water homeostasis, primary emotional reactions of aversion/craving, as well as the control of the sleep-wakefulness cycle [6]. Four major CP topographies depending on the specific type of CP-TVF relationship were identified: i) suprasellar-pseudointraventricular CPs: the category of lesions usually originated at the junction between the pituitary gland and stalk that expand within the suprasellar cistern while causing an upward displacement of the TVF, mimicking an intraventricular position; ii) sellar/suprasellar-secondary intraventricular CPs: lesions initially develop under the 3V but at later stages invade and occupy the 3V cavity after breaking through the TVF; iii) infundibulo-tuberal or not-strictly intraventricular CPs: tumors developed at a subpial position within the neural layer of the infundibulum or tuber cinereum and expanding predominantly into the 3V(These lesions grow in close contact to the hypothalamic nuclei [3, 4]); and iv) strictly-intraventricular CPs: tumors primarily developed within the 3V, above an intact TVF [4, 6, 62]. An additional topographical category of CPs without 3V involvement has to be considered, the group of sellar-suprasellar CPs that includes those tumors originated at the dorsal surface of the pituitary gland, beneath the sellar diaphragm, which exclusively occupy the sellar and/or suprasellar compartments (Figure 1). This scheme is relatively simple and has the major advantage of providing essential information about the type of hypothalamic-CP relationship that will be found during the surgical procedure. Furthermore, the relative position of the hypothalamus and its degree of anatomical distortion can be easily ascertained on preoperative MRI studies by defining the CP topography according to these categories [8, 9]. In our topographical scheme, the category of sellar-suprasellar CPs is the one associating the lowest risk of hypothalamic injury, whereas the surgical risk is maximal for the secondarily-intraventricular and infundibulo-tuberal topographies that are characterized by wide and strong adhesions to the hypothalamus [7].

Figure 1 Topographical classification scheme for craniopharyngiomas based on the original point of development along the hypothalamic-hypophyseal axis [3, 6]. Left: Illustrative mid-sagittal schematic of the hypothalamic-hypophyseal complex. The lower part of the hypothalamus surrounding the infundibular recess (IR) corresponds to the infundibulum. CPs may originate at four different points along this vertical axis: i) at the dorsal surface of the pituitary gland (1); ii) from the pars tuberalis covering the infundibular stem or pituitary stalk (2); iii) at a subpial position within the neural tissue of the median eminence (ME) and the tuber cinereum (TC) of the third ventricle floor (3); iv) wholly within the third ventricle, from beneath the ependymal layer of the infundibulum (4). A: arquate nucleus; Ch: optic chiasm; DM: dorsomedial nucleus; ds: diaphragma sellae (in blue); M: medial mammillary nucleus; MB: mammillary body; P: posterior nucleus; PD: pars distalis; PI: pars intermediate; PN: pars nervosa; PV: paraventricular nucleus; SO: supraoptic nucleus; TM: tuberomammillary nucleus; VM: ventromedial nucleus; 3V: third ventricle. Right: Tumor-hypothalamus anatomical relationships for the five major CP categories considered in our topographical classification: i) sellar-suprasellar; ii) sellar/suprasellar pseudointraventricular (S-SS-Pseudo 3V); iii) sellar/suprasellar secondary intraventricular (S-SS-Secondary 3V); iv) not-strictly intraventricular (Not-strictly 3V) or infundibulo-tuberal; v) strictly intraventricular (strictly 3V). Column A shows the tumor-hypothalamus relationships as observed on mid-sagittal MRI scans. Column B illustrates these relationships as seen in coronal trans-infundibular sections. The position of the hypothalamus (in red) relative to the tumor is indicated for each topographical category. The color of the frame for each topographical category corresponds to the number of the point of origin along the hypothalamic-hypophyseal axis.

3.3 The Category of Infundibulo-tuberal Craniopharyngiomas: Clinical Assessment and Surgical Risks

The category of not-strictly intraventricular or infundibulo-tuberal CPs deserves special address due to the fact that it is the most prevalent topography in both adults and children, with an overall rate between 30 and 50% of cases, and high surgical risk [1, 6, 33, 42, 52-54, 72]. Infundibulo-tuberal CPs originate in the basal region of the hypothalamus within the TVF, an anatomical area formed by the infundibulum (Figure 1), the hollow and funnel-shaped proximal portion of the neurohypophysis, and the tuber cinereum, the adjacent grey matter enclosed between the optic tracts and the mamillary bodies [30, 75]. Mortality rates reported for this topography range between 4 and 15%, and postoperative morbidity due to hypothalamic injury, including lethargy, apathy, progressive obesity, severe memory loss, and behavioral or psychiatric disturbances may occur in up to 50% of patients, whose quality of life becomes notably hampered [76]. The underlying reason for such a high risk of hypothalamic damage is the subpial origin of this CP category leading to the close contact between the tumor capsule and the hypothalamic nuclei without any protective intervening meningeal layer.

The median eminence (Figure 1), located along the midline of the infundibulum, contains the arcuate nucleus, which plays a fundamental role in the regulation of feeding behavior linked to energy balance. In addition, the lower ventromedial, periventricular and tubero-mamillary nuclei, as well as the supra-optic-hypophyseal and tubero-hypophysial tracts included within the infundibulo-tuberal region are involved in the regulation of water metabolism, control of sleep cycles and sexual functions through the monitoring of circulating sexual hormones and the control of hypophyseal secretion of gonadotropins [30, 77-81]. Apart from a thorough assessment of MRI studies, the preoperative identification of symptoms caused by dysfunction of these hypothalamic basal structures is essential to predict the anatomical and functional status of the infundibulum and tuber cinereum. The infundibulo-tuberal syndrome can be observed in patients with a functional impairment of the infundibulum and tuber cinereum, and is manifested by symptoms such as abnormal somnolence, diabetes insipidus and/or adipose-genital syndrome [82]. This adipose-genital syndrome, also known as Fröhlich’s syndrome, consists of sexual infantilism and abnormal obesity [23]. Despite the surgeon’s experience and clinical skills, any forcible attempts at radical CP removal in patients with symptoms of the infundibulo-tuberal syndrome can lead to a high risk of irreversible hypothalamic injury and severe postoperative morbidity or even patient death [4, 65, 82].

The infundibulo-tuberal CP topography makes the greatest controversy regarding the feasibility of achieving a radical resection. Some surgeons, led by William H. Sweet (1910-2001) considered the layer of gliosis developed around these tumors as a viable cleavage plane for a safe and radical removal [44, 84]. On the contrary, histological/pathological evidence has shown a true fusion between the tumor and the surrounding hypothalamus, rendering a total excision impracticable. The generation of a sticky layer of reactive gliosis at the TVF remnants around the tumor additionally contributes to the strong, extensive adhesions usually found in this subgroup [83]. Both Bailey and Northfield emphasized that extreme adhesiveness of the glial layer was a sign indicating that the cleavage plane was positioned within the normal hypothalamus [29, 59]. Actually, the overall rate of total resection for the infundibulo-tuberal category is only about 60%, a percentage notably lower than that reported for other CP categories. This indicates the difficulty of releasing the tumor from the hypothalamic adhesions and/or the neurosurgeon’s determination to leave untouched the tumor fragments strongly attached to the floor/walls of the 3V in these cases [76]. In support of such a conscious decision, Kubota’s et al. analysis of the brain-tumor interphase in 6 whole CP specimens predominantly growing inside the 3V found that the layer of peritumoral gliosis had an irregular thickness and, in some areas, no effective distance for a safe dissection could be identified between the tumor and the adjacent hypothalamic nuclei [73]. Likewise, several authors have evidenced the presence of tumor finger-like protrusions penetrating into the adjacent hypothalamus [85-87], a decisive histological finding suggesting the cautious assessment of CP-hypothalamus adhesions and warning against the indiscriminate radical removal of infundibulo-tuberal CPs.

4. Craniopharyngioma Adherence: From a Neurosurgeon’s Subjective Notion to an Objective Definition of Adhesion Pattern and Severity

Apart from the neurosurgeon’s skill, patient outcome following CP removal mainly depends on the type and strength of tumor adhesion to the hypothalamus [7, 88]. The pervasive uncertainty regarding the extent and degree of adhesion in each case is a source of great distress for the neurosurgeon. The extreme heterogeneity of tumor adhesions has surely contributed to the lack of a reliable description of this pathological feature in most modern CP surgical series. We have recently been able to address this issue through the methodical examination of 500 well-described CPs, including non-operated whole tumors from brain autopsy specimens as well as surgically treated cases. We were able to identify repetitive patterns of CP adhesion associated with specific tumor topographies and to present the first comprehensive classification of CP adherence [7]. Furthermore, our methodology allows for an accurate, reliable assessment of the pattern and strength of CP adhesions employing conventional MRI studies [9]. This model provides an objective way of grading the type of CP-hypothalamus adhesions into five major levels of severity, each one associating an increasing risk of hypothalamic injury during surgery. A critical understanding of surgical risks based on the severity of CP adhesions to the hypothalamus defined on preoperative MRI may be a fundamental tool for guiding the neurosurgeons’ decision regarding the safest approach to the tumor and extent of removal to be carried out in each patient [7,9].

4.1 The Three Components of Craniopharyngioma Adherence

The type of tumor adherence can be objectively defined according to three components:

Anatomical structures involved in the adhesion. This component defines the structure of the hypothalamic-pituitary axis to which the tumor shows the predominant or primary adhesion. The maximal adhesion is usually observed at the anatomical structure where the CP originally develops. According to the anatomical structure involved, the following types of attachment can be differentiated (Figure 2): i) attachment to the pituitary gland and/or sella turcica, below the diaphragm sellae; ii) attachment to the pituitary stalk and outer surface of the infundibulum; iii) attachment to the entire thickness of the TVF; iv) attachment to the 3V floor and walls; v) attachment to the ependymal lining of the 3V; vi) attachment to the whole hypophyseal-hypothalamic axis.

Morphological pattern of CP adhesion. This component defines the extent and shape of the CP adhesions, and six patterns can be distinguished (Figure 3): i) pedicle-like attachment, formed by a narrow fibro-vascular stem between the tumor base and the ependyma of the 3V, usually observed in purely or strictly intraventricular CPs; ii) sessile or “patch-like” attachment, in which a limited area of the tumor surface forms the adhesion, usually to the pituitary stalk and/or infundibulum; iii) “cap-like” adhesion, involving the upper half of the tumor, usually visible in large CPs pushing the 3V upwards (pseudointraventricular CPs); iv) ring-like attachment, in which a band of adhesion encircles the tumor’s central portion, usually observed in tumors invading the 3V (secondarily 3V CPs) and also in CPs developed within the TVF itself (infundibulo-tuberal CPs). As this band of adhesion is usually formed by the nervous tissue remnants of the TVF, it represents a close, hazardous-to-touch plane contact between the CP and the hypothalamus; v) “bowl-like” adhesion, in which the tumor’s bottom part is attached to the TVF, observed among CPs expanding within the 3V; vi) circumferential adhesion, the most extensive type of attachment in which the surrounding brain tissue wraps around the entire tumor surface, typical of infundibulo-tuberal CPs.

Figure 2 First component of craniopharyngioma adherence: intracranial structures involved in the attachment [7]. Six major adhesion patterns can be considered: A. Sella-Gland: tumor attachment occurs within the sella turcica to the pituitary gland and/or the sellar structures below the diaphragm sellae. B. Outer aspect of the Stalk-Infundibulum: the CP attachment occurs at the solid portion of the pituitary stalk and the outer aspect of the infundibulum. C. Third ventricle floor (TVF): the tumor is adhered to the entire thickness of the TVF. D. TVF-3V walls: CP attachment involves the floor and walls of the third ventricle. E. 3V (inner lining): the tumor is attached to the ependymal lining of the third ventricle cavity. F. Global (Sella to 3V): the CP attachment involves all the structures of the hypophyseal-hypothalamic axis.

Figure 3 Second component of craniopharyngioma adherence: morphology or extent of the attachment [7]. Six major patterns can be distinguished: A. Pedicle: the tumor is attached through a narrow fibrovascular stem. B. Sessile: small patch of adhesion. C. Cap-like: wide adhesion involving the upper half of the tumor. D. Ring-like: a circular band of brain tissue (the TVF) is encircling the central portion of the tumor surface. E. Bowl-like: wide adhesion to the infundibulo-tuberal region involving the lower half of the tumor. F. Circumferential: the entire tumor surface is attached to the surrounding brain tissue (hypothalamus).

Strength of CP adhesion. This component describes the resistance offered by the attachment to surgical release and can be classified in four types (Figure 4): i) loose or easily dissectible adhesions; ii) tight adhesions, for which a sharp dissection is required to preserve the anatomical structure attached; iii) CP-brain or CP-pituitary stalk fusion, when there is no identifiable cleavage plane between the tumor and the adjacent nervous tissue; iv) replacement, the strongest and most dangerous degree of adhesion occurs when the structure involved in the attachment is no longer recognizable because it has been replaced by tumor growth. The infundibulum and tuber cinereum of the TVF are usually replaced by large infundibulo-tuberal CPs as well as by secondarily 3V lesions encroaching upon the 3V.

Figure 4 Third component of Craniopharyngioma adherence: adhesion strength [7]. Four major patterns can be identified: A. Loose: easily dissectible adhesion. Note the arachnoid layer (arrows) interposed between the tumor (t) and the normal brain; B. Tight: No meningeal layer is interposed between the tumor (t) and the anatomical structure. Sharp tumor dissection is mandatory to preserve the brain structure attached. PG: pituitary gland; PS: pituitary stalk; C. Fusion: a cleavage plane between the tumor and the adjacent brain tissue cannot be identified; D. Replacement: the structure involved in the attachment is no longer recognizable, as it has been encroached upon and replaced by the tumor. Ch: optic chiasm; MB: mamillary body.

4.2 Craniopharyngioma Adhesions Classified into Five Levels of Adherence Severity

Taking into consideration the three components of tumor adhesion, the severity of CP adherence can be classified into 5 major levels—mild, moderate, serious, severe, and critical (Figure 5)—each associating an increasingly higher risk of hypothalamic injury and a worse postoperative outcome [7]. The least severe type of hypothalamic adhesion (level I or mild) occurs more often in wholly intrasellar or sellar-suprasellar CPs separated from the TVF by a meningeal layer, either the dura mater of the diaphragm sellae or the arachnoid membranes of the chiasmatic cistern. Level II or moderate severity is typically observed in strictly intraventricular CPs with a pedicle or a sessile attachment to the ependymal lining of the 3V, a type of adhesion which can usually be released straightforwardly. Level III (serious) adhesion is found in suprasellar CPs tightly adhered or fused to the pial surface of the infundibulum and/or tuber cinereum, without any intervening arachnoid layer. Attempts at releasing the tumor from these adhesions to the outer surface of the median eminence/basal hypothalamus associated a poor outcome in about one tenth of the cases. Level IV (severe) occurs in CPs fused to the TVF nervous tissue or those replacing the infundibulo-tuberal region. These extensive adhesions to the hypothalamus are usually observed in infundibulo-tuberal CPs and in tumors invading the 3V. Severe CP adhesions usually show a bowl-like, ring-like or circumferential morphology, and forceful attempts to separate the tumor from the adjacent hypothalamus led to a poor outcome in about 25% of cases due to irreversible hypothalamic damage. Finally, level V, the most severe (critical) degree of hypothalamic adherence occurs in large and aggressive CPs extending from the sella to the 3V roof that encroach upon all the structures of the pituitary-hypothalamic axis. The invasion and replacement of the TVF led to a rate of poor outcome/death as high as 40% in this group [7].

Figure 5 Severity levels of craniopharyngioma adherence to the hypothalamus. The first row shows autopsy specimens of CPs (t) for the five adherence severity levels (I to V) considered. The middle and lower rows display preoperative and postoperative MRI scans, respectively, of tumors presenting similar adherence severity levels to those shown in the autopsy specimens. The red arrows point to the position of the hypothalamus relative to the tumor. The table at the bottom summarizes the specific three components of CP adherence that define each level of severity. Level I - Mild: A1. Midsagittal brain section showing a sellar-suprasellar CP (t) which displaced the third ventricle floor upward (red arrow). MB: mamillary body; 3V: third ventricle. A2. Preoperative midsagittal section showing a sellar-suprasellar CP (t). Note the hypothalamus (red arrow) is above the tumor. Ch: optic chiasm. A3. Postoperative scan demonstrating the anatomical integrity of the third ventricle floor (TVF) following radical tumor removal through a pterional route. Level II - Moderate: B1. Coronal autopsy specimen showing a strictly intraventricular papillary CP (t) with a small basal attachment (blue arrow) to the TVF (red arrows). B2. Preoperative MRI scan of a solid strictly intraventricular CP (t). Note the pituitary stalk (PS) and the pituitary gland (PG) are intact below the tumor. B3. Postoperative scan demonstrating an intact TVF following a complete tumor resection through a pterional trans-lamina terminalis approach. Level III - Serious: C1. Sellar-suprasellar pseudointraventricular CP (t) beneath an upwardly displaced TVF (red arrow). C2. Preoperative midsagittal MRI scan showing a pesudointraventricular CP (t) pushing the TVF upward and stretching the chiasm (Ch). C3. Contrast-enhanced areas can be observed at the upper pituitary stalk (PS) and the outer side of the infundibulo-tuberal area (arrows), a sign of residual tumor/gliotic scarring after blunt dissection of a tightly attached tumor which was approached through a pterional route. Level IV - Severe: D1. Not-strictly intraventricular or infundibulotuberal CP (t) with a mixed solid-cystic consistency. Note the MB is the only visible TVF structure. The pituitary stalk (PS) has been amputated by the tumor and the pituitary gland (PG) is intact beneath the tumor. D2. Coronal preoperative MRI scan showing an infundibulo-tuberal CP (t). The hypothalamus is located around the mid-third portion of the tumor (red arrows). D3. Postoperative scan revealing a hypointense sign on the left hypothalamus (arrow), indicating hypothalamic injury after radical trans-lamina terminalis tumor resection. Level V - Critical: E1. Sagittal section showing a suprasellar-secondary intraventricular CP (t) that has broken into the third ventricle. E2. Preoperative MRI scan showing a large multilobulated secondary intraventricular CP (t). The hypothalamus (red arrows) is around the mid-third portion of the tumor. E3. Postoperative contrast-enhanced T1-weighted MRI scan, following a radical transcallosal removal, shows a breached TVF (asterisk), a sign suggesting tumor replacement of the tuber cinereum. The hyperintense sign at the TVF remnants (arrow), indicates the presence of gliotic scarring and/or tumor remnants.

5. Diagnosis of CP Topography: MRI Predictors of the Tumor-Hypothalamus Relationship

Since the introduction of MRI in the late 1980s, this technology represents the gold standard tool for the preoperative diagnosis of CPs, despite CT remaining more useful to depict tumor calcifications. MRI allows an accurate assessment of the tumor’s anatomical relationships in the three spatial dimensions [89]. Preoperatively recognizing the true hypothalamus position regarding the tumor, as well as the anatomical distortion of this structure, represents essential information for the neurosurgeon to anticipate the risks of hypothalamic injury and to plan accordingly the most suitable surgical procedure. Our group has recently demonstrated that an accurate definition of CP topography (Figure 6) and the type of CP-hypothalamus adhesion (Figure 7) can be reliably achieved with conventional MRI by examining the T1- and T2-weighted sequences [8, 9]. Midsagittal and coronal-transinfundibular MRI sections are the two most important ones for a proper assessment, as CPs originate along the midline structures that form the pituitary-hypothalamic axis. By assessing a small set of MRI signs, it is possible to achieve a correct preoperative definition of CP topography and hypothalamic adhesion severity in a high rate of patients, 85% and 90% of cases respectively [8, 9]. Preoperative MRI evaluation must include the occupation by the tumor of the intracranial anatomical compartments surrounding the pituitary-hypothalamic axis (sella turcica, chiasmatic-or suprasellar- cistern and 3V), in addition to the anatomic distortion of the pituitary-hypothalamic structures (pituitary gland, pituitary stalk, infundibulum, tuber cinereum and third ventricle walls).

5.1 Tumor Occupation of the Third Ventricle and the Chiasmatic Cistern

The compartments whose occupation provide the most reliable information to define CP-hypothalamus relationships are the 3V and the chiasmatic-or-suprasellar cistern. No occupation of the 3V is only observed in the sellar-suprasellar topography, the one associating the lowest risk of hypothalamic injury (Figure 6. A1). Although extremely important, accurately distinguishing between the four remaining topographical categories involving the 3V is more difficult, and the occupation of the chiasmatic cistern represents one of the most valuable radiological signs. A wholly tumor-free chiasmatic cistern strongly points to the strictly intraventricular topography (Figure 6. E1), whereas its partial occupation (“belly-like” protrusion) is typical of the infundibulo-tuberal category (Figure 6. D1). Complete obliteration of the chiasmatic cistern may be observed in tumors originated below the TVF (suprasellar-pseudointraventricular or secondary intraventricular topographies) (Figure 6. A1, B1, C1) [8].

5.2 Pituitary Stalk Distortions

The anatomical distortions of the pituitary-hypothalamic axis, in particular the appearance of the pituitary stalk and the anatomical position the hypothalamus relative to the tumor, are the two most useful MRI signs to define the type of CP-hypothalamus relationship. The appearance of the pituitary stalk is the radiological sign showing the strongest correlation with the type of CP topography [8]. Four major patterns of stalk distortion can be differentiated on preoperative MRI scans: intact or wholly visible; thickened; amputated; and not visible. Amputation of the upper infundibular portion of the stalk by the tumor is usually observed in the not-strictly intraventricular or infundibulo-tuberal topography (Figure 6. D1). This sign strongly suggests the presence of a severe (level IV) CP adhesion to the hypothalamus. On the contrary, a normal pituitary stalk appearance points to the strictly intraventricular topography with a moderate (level II) adherence to the hypothalamus (Figure 6. E1). Inability to identify the pituitary stalk on preoperative MRI is a less specific sign, as this can occur in any of the three CP topographies that originate beneath the TVF and occupy the chiasmatic cistern: the sellar-suprasellar, pseudointraventricular and secondary intraventricular topographies, all of which encroach upon the whole pituitary stalk (Figure 6. A1, B1, C1).

5.3 Hypothalamus Position Relative to the Tumor

The level of the hypothalamus relative to the tumor is the most informative MRI sign to predict the severity of CP adherence [9]. This variable is best assessed on coronal-transinfundibular MRI sections, and three major positions can be considered: hypothalamus located at the bottom of the tumor area; around its mid-third portion; or above the top pole of the lesion. When the hypothalamus is located around the mid-third or central portion of the tumor, the presence of extensive and tenacious adhesions to the hypothalamus, with either a ring-like or a circumferential pattern (high-risk adherence levels, IV-severe or V-critical), should be expected (Figure 7. D2, E2). On the contrary, when the hypothalamus is located either around the lower third (Figure 7. B2) or upper third of the tumor (Figure 7. A2, C2), low-risk adherence levels (I-mild, II-moderate, or III-serious) are likely to be found [9]. A hypothalamus positioned at the lower third of the tumor is typically observed in the strictly intraventricular topography (Figure 6. E2), whereas a hypothalamus situated above the tumor pole generally occurs in the sellar-suprasellar (Figure 6. A2) or pseudointraventricular (Figure 6. B2) topographies [8].

Figure 6 MRI signs defining the five major topographical craniopharyngioma categories. Midsagittal (A1 to E1) and coronal-transinfundibular (A2 to E2) MRI sections representative of each category. Red arrows point to the relative position of the hypothalamus in relation to the tumor. Blue angles formed by the intersection of a plane tangential to the base of the mamillary bodies (MB) with the plane tangential to the fourth ventricle floor forms the mamillary body angle. Ch: chiasm; t: tumor; 3V: third ventricle. The table below summarizes the specific MRI signs observed for each topographical category.

5.4 Craniopharyngioma Shape

Some macroscopic CP features, such as tumor size, consistency, shape, or presence of calcifications, provide key information about the extent and degree of CP adhesions, and should also be defined on preoperative neuroradiological studies. Among these features, tumor shape has proven particularly useful to predict the severity of CP-hypothalamus adhesions. A pear-like tumor outline is typical of CPs originated within the sellar compartment which have pushed the diaphragm sellae upward against the optic chiasm as they grow (Figure 7. A2). The presence of this layer of duramater interposed between the tumor and the TVF prevents the development of tight adhesions to the hypothalamus in these cases, associating the lowest risk of hypothalamic injury. Quite the opposite, a multilobulated morphology indicates that the tumor originated along the PS, at the level of the chiasmatic -suprasellar- cistern, and that it expanded into the arachnoid spaces, giving rise to more extensive and sticky adhesions to the hypothalamus (Figure 7. E2). Finally, the elliptical shape is associated with the tumors showing the most severe degrees of hypothalamic attachment (levels IV and V) (Figure 7. D2) [9]. Two additional, highly informative MRI signs that should be evaluated on preoperative MRI studies are the mamillary body angle and the anatomical distortion of the optic chiasm, both of which will be described below.

Figure 7 Surgical findings and MRI signs defining the five increasing severity levels of craniopharyngioma adherence. The bottom table summarizes the specific MRI signs associated with each CP adherence severity level. Level I - Mild: A1. Right pterional view showing the arachnoid layer (arrow) between the tumor (t) and the surrounding structures. ICA: internal carotid artery; rON: right optic nerve. A2. Midsagittal MRI scan showing a craniopharyngioma with a pear-like morphology (t) expanding in the sellar and suprasellar compartments below the hypothalamus (red arrow). The pituitary stalk cannot be identified. Level II - Moderate: B1. Surgical view through a right pterional approach showing the narrow pedicle attachment (arrow) of a papillary CP (t) to an intact third ventricle floor (TVF) below the tumor. B2. Midsagittal MRI scan of a round solid tumor (t) purely located in the third ventricle. Note the hypothalamus (red arrow) is below the tumor and the pituitary stalk (PS) has a normal appearance. Level III - Serious: C1. Right pterional view showing a tight adhesion (arrow) between the tumor and the upwardly displaced chiasm and third ventricle floor. C2. MRI scan showing a dumbbell CP (t) that displaces the chiasm and third ventricle floor (red arrow) upward, mimicking an intraventricular position. Level IV - Severe: D1. Intraoperative view through a right pterional approach showing a CP (t) fused (arrows) to the inner surface of the infundibulum (IF). D2. Coronal MRI scan showing an elliptical tumor (t) that predominantly expands into the third ventricle and partially occupies the chiasmatic cistern. Note the pituitary stalk (PS) has been amputated. The hypothalamus is positioned around the mid-third of the tumor. Level V - Critical: E1. Intraoperative view through the lamina terminalis after complete tumor removal. The basilar artery (B) and the right posterior cerebral artery (P1) are observed through the broken TVF (asterisk). E2. Coronal MRI scan showing a large multilobulated CP (t) expanding from the sella to the third ventricle. The pituitary stalk is not visible and the hypothalamus is located at the mid-third portion of the tumor (red arrows).

5.5 The Mamillary Body Angle

Identification of the position and anatomical status of the whole TVF on conventional MRI studies from CP patients is quite difficult, particularly when CPs are larger than 3cm because the infundibulum and tuber cinereum are severely distorted, and they cannot usually be distinguished from the CP capsule. The compact structure of the mamillary bodies (MBs), as they remain the only identifiable component of the TVF in many cases. Based on this observation, our group defined in 2013 the mammillary body angle (MBA) as a useful radiological tool to ascertain the position of the TVF regarding the tumor [62]. The MBA is defined as the angle formed by the intersection of the plane tangential to the base of the mammillary bodies with the plane tangential to the fourth ventricle floor (Figure 8). This angle can easily be measured on midsagittal MRI scans (Figure 6. A1-D1). In healthy individuals without intracranial pathology, the normal MBA value usually ranges between 50° and 70°. CP growth causes a progressive displacement and distortion of both the TVF and the MBs, and a change in the MBA value can be correlated with the TVF status, depending on the original site of tumor development along the pituitary-hypothalamus axis (Figure 8). Thus, this radiological sign has proven useful to predict CP topography. Tumors originated below the TVF at a sellar/suprasellar position typically cause an upward displacement of the mamillary bodies, shifting the MBA towards an obtuse value (>90°) (Figure 6. B1). An obtuse MBA is a strong predictor of the pseudointraventricular CP topography. By contrast, an acute MBA (<90°) is usually observed in intraventricular CPs displacing the TVF downwards as they expand within the 3V. The MBA value becomes even more reduced (hyperacute, <30°) in cases of CPs originating within the TVF itself (not-strictly intraventricular or infundibulotuberal CPs) (Figure 6. D1), as these tumors push the MBs against the midbrain while expanding within the tuber cinereum [62]. Consequently, a hyperacute MBA strongly suggests a severe CP-hypothalamic adhesion, usually between the central portion of the tumor and the remnants of the TVF.

Figure 8 The mamillary body angle (MBA) and its relation to craniopharyngioma topography. A: scheme illustrating how the MBA is measured on a midsagittal section. The MBA is formed by the intersection of the plane tangential to the base of the mamillary bodies (MBs) with the plane tangential to the floor of the fourth ventricle. Normal MBA ranges from 30º to 60º. B: Not-strictly intraventricular or infundibulotuberal CPs (t) developed in the TVF itself typically show hyperacute MBAs as the MBs are displaced towards the midbrain during tumor enlargement. C: Pseudointraventricular CPs (t) originated in the suprasellar cistern push the TVF upward towards the fornices and roof of the 3V leading to an increase in the MBA value (obtuse MBA).

5.6 Optic Chiasm Distortions

Visual impairment is one of the major and earliest presenting symptoms among CP patients. This deficit is due to the progressive distortion of the optic chiasm by the tumor. The direction and severity of optic chiasm distortion is mainly related to the original site of tumor development, and will significantly influence the severity and outcome of visual deficits. Our group systematically analyzed these distortions in a cohort of well described CP cases, and we were able to identify repetitive chiasm distortion patterns associated with specific tumor topographies [90]. The chiasm distortion types showed a strong correlation with the severity of visual deficits and their reversibility after tumor removal. Two major types of chiasm distortion could be identified on midsagittal MRI sections: compression and stretching (Figure 9). Compressed chiasms are characterized by a crescent and swollen appearance, a deformation that is typically caused by CPs originated within the TVF at the same level or slightly above the horizontal plane of the chiasm (Figure 9. B.). In contrast, stretched chiasms show an elongated and thinned appearance after being pushed upwards by a tumor growing below or in front of the chiasm plane (Figure 9. C.). In addition to the shape alteration, the optic chiasm may be displaced in a preferential direction by the tumor growth. Among the compressed chiasms, two major subgroups can be distinguished: i) chiasm compressed downward, when the chiasm is slightly pushed and displaced beneath the lower pole of the tumor (Figure 9. B1.); ii) chiasm compressed forward, when this structure is displaced towards the tuberculum sellae and smashed against this bony structure (Figure 9. B.2.). Among stretched chiasms, three major displacements may occur: i) stretched forward, when the chiasm is elongated along the anterior margin of the tumor (Figure 9. C.1.); ii) stretched upward, when it is elongated over the tumor dome (Figure 9. C.2.); and, iii) stretched backward, when it is elongated along the posterior margin of the tumor (Figure 9. C.3.) [90].

The importance of identifying these optic chiasm distortion patterns on preoperative MRI scans is to assess their correlation with the presence and severity of specific visual deficits and with the postoperative visual outcome [90]. For example, vision is not impaired in 80% of CP patients whose optic chiasm shows a normal appearance or a downward compression. These cases also associate the best visual outcome. On the contrary, more than 80% of patients with either forward compressed or stretched distortions have visual deficits. The upward stretched pattern associates a rate of severe visual disturbances as high as 75%, as well as the worst visual outcome. About one third of CP patients with a chiasm stretched upward will not experience any visual improvement following tumor removal. This poor visual outcome is probably the result of an irreversible axonal degeneration caused by the effect of three simultaneous mechanical deformations: elongation of the fibers; compression of the optic nerves at the level of the sharp bone edges of the optic foramina; and strangulation of the dorsal surface of the chiasm by the anterior communicating artery complex (Figure 9.C). The type of optic chiasm distortion is also a valuable MRI sign to predict the CP topography [90]. Strictly, intraventricular CPs typically do not cause any deformation to the optic chiasm (Figure 9. A1.), or they only slightly compress it downwards (Figure 9. B1.). On the contrary, the forward compressed distortion points to the not-strictly intraventricular category (Figure 9. B.2.), chiasms stretched forward suggest a secondary intraventricular position (Figure 9. C.1.) and the upward stretched alteration is usually observed in the pseudointraventricular and sellar-suprasellar topographies (Figure 9. C.2.) [90].

Figure 9 Optic chiasm distortions caused by craniopharyngiomas as relates to tumor topography. The upper row shows schematic drawings of the three major types of chiasm distortions found in CP cases. The lower panels show midsagittal MRI scans of representative cases. A. Normal chiasm: a normal chiasm shape and position is typically found in tumors (t) with a strictly intraventricular topography (A1). B. Compressed chiasm: a chiasm with a swollen appearance is generally found in intraventricular-retrochiasmatic CPs (t) that push the chiasm towards the planum sphenoidale (arrows). The compressed distortion is subclassified into downward displaced chiasm at the antero-inferior margin of the tumor (B1), and forward displaced chiasm, pushing against the tuberculum sellae (B2). C. Stretched chiasm: elongation of the chiasm generally occurs with CPs (t) originated beneath the third ventricle floor. Arrows indicate the three mechanisms involved in damaging the optic fibers: i) compression of the optic nerves by the sharp bone edges of the optic foramina (grey arrows); ii) elongation of the chiasm (white arrows); and iii) strangulation of the chiasm dorsal surface by the A1-anterior communicating artery complex (black arrows). Three subgroups can be identified depending on the displacement direction: forward (C1); upward (C2); and backward (C3).

6. The Impact of Topography and Adherence on Craniopharyngioma Recurrence

Together with hypothalamic injury, CP recurrence represents a formidable challenge posed by these complex tumors. This is mainly due to the difficulty in predicting such recurrence, in addition to the high morbidity and mortality rates associated with surgery of recurrent tumors [91]. Moreover, the rate of patients affected by CP recurrence is rather high, as one third overall of these tumors recur after a 3-year postoperative interval. For these reasons, there has recently been a growing interest in using molecular changes present in CP cells as a potential tool to predict the likelihood of tumor recurrence [18]. Unfortunately, there is no agreement on the actual reliability of molecular alterations to predict CP recurrence. Lack of clear conclusions are probably due to the fact that most molecular studies have the shortcoming of analyzing the CP molecular profile without taking into consideration the individual type of treatment and pathological features of each tumor, among them CP topography and tumor adhesion pattern [18].

Most authors agree that an incomplete tumor removal is the major predictor of CP recurrence [91]. Apart from the surgeons’ skills, accurate CP topography and type of tumor adhesion are the major factors that will determine the possibility of achieving a complete tumor removal. A correct definition of these pathological factors must be established prior to any attempt at analyzing the impact of the molecular changes in CP recurrence. For example, it should be noted that the wide and strong adhesions to the surrounding brain observed in infundibulo-tuberal CPs, as well as the common microscopic finding of finger-like tumor protrusions into the hypothalamus that characterize this topography, are two causes explaining why tumor remnants can be left behind unintentionally even after an apparently gross total removal [4, 91]. On the contrary, strictly intraventricular CPs, particularly those with a squamous papillary histology, are generally characterized by a clear and loose cleavage plane between the tumor and the hypothalamus, except at the point of a small pedicle/patch attachment to the TVF, that generally allows for a complete removal [5, 6, 34]. Thus, the molecular changes in these two topographical categories are not comparable, and a stratified analysis of the molecular alterations for each topography and degree of tumor removal is necessary.

7. CP Topography: The Fundamental Variable in Selecting a Surgical Approach

A wide range of surgical approaches have been employed for CPs, such as the pterional, subfrontal, transsphenoidal, transcallosal, frontal-trans-ventricular and interhemispheric. Overall, the surgeon’s experience and preference have normally dictated the particular chosen approach . Nevertheless, different CP topographies and adhesion patterns support the concept that certain routes are more suitable than others for specific CP-hypothalamus relationships. Therefore, an essential aspect of CP surgical planning is to decide “where to begin”. The optimal surgical route is that which provides a direct and broad view of the tumor-brain cleavage plane, particularly of the expected areas of maximal adhesion to the hypothalamus [1, 33, 42, 49, 55, 58, 84].

The upper trans-ventricular routes can only be used safely in strictly intraventricular CPs, as in these cases the hypothalamus is situated below the tumor (Figure 6. E.2.). These lesions typically present small attachments to the inner side of the TVF (Figure 7. B.1.) that can usually be released straightforwardly through a trasncallosal or frontal-transventricular approach [6, 46, 92, 93]. However, these routes associate a high risk of iatrogenic hypothalamic injury when used to remove any of the remaining topographical CP categories involving the 3V [2, 38, 66, 94]. The reason is that upper trans-ventricular approaches do not offer a direct view of the basal hypothalamus, the region to which most not-strictly intraventricular and secondary intraventricular CPs are strongly attached. The trans-lamina terminalis approach, either through a pterional, subfrontal or interhemispheric route, provides a direct view of the TVF where the attachments of any intraventricular CP are located, and is therefore suitable to remove either strictly or not-strictly intraventricular tumors [5,6,31,46,92,95]. Some authors such as Yasargil and Steno favored the use of combined basal and upper approaches to have a complete view of the tumor-hypothalamus surface [2,49].

In the last ten years, the use of endoscopic endonasal transsphenoidal routes to remove CPs has been expanding [55,57,58]. The major advantage of this route is that it fully exposes the tumor-hypothalamus adhesion plane present in tumors developing within the infundibulum (infundibulo-tuberal CPs) and in suprasellar lesions invading the 3V (secondary-intraventricular CPs). Nevertheless, the advantage of performing a sharp dissection under direct view should be counterbalanced by the high risk of cerebrospinal fluid fistula due to the direct connection which will remain between the 3V and the nose, particularly when this approach is used by non-experts [96,97].

8. CP-Hypothalamus Adherence Severity: The Fundamental Factor in Deciding the Degree of Tumor Removal

The debate about the solid decision of tumor removal is still highly controversial among experts on CP treatment. Most neurosurgeons agree that a complete tumor resection is the optimal way of reducing the chances of tumor recurrence and the hazardous procedures for treating recurrent CPs, but many others advocate a conservative, incomplete removal to reduce the risk of hypothalamic damage and the long-term associated invalidating sequelae [66,98,99,100]. Nevertheless, we firmly believe that the decision regarding the degree of tumor removal should not be based on a specific technique or opinion but rather on the individual CP topography and its pattern of adherence. Thus, aside from the surgical approach, the second aspect of the surgical planning to be considered, is “when to stop”. An accurate preoperative definition of the risk of hypothalamic injury for each case is essential to take the proper decision about the degree of tumor removal most suitable. This aspect of surgical planning should also be part of patient counselling.

Conventional MRI studies can correctly identify the CPs presenting the most severe adhesions to the hypothalamus (levels IV and V) in approximately 90% of cases [9]. The MRI signs that predict hypothalamic adherence with a high surgical risk are the position of the hypothalamus around the mid-third of the tumor, the amputation of the pituitary stalk and an elliptical tumor shape. In most of these cases a radical removal would inevitably lead to irreversible hypothalamic injury, and therefore an incomplete tumor removal is strongly advocated.

9. Conclusions

The widespread, inaccurate use of the term “suprasellar” to define CP topography should be abandoned and replaced by an accurate definition in each case. Most CPs actually involve the 3V, and a rate as high as 40% originate in the infundibulum or tuber cinereum, growing in close contact with the hypothalamus. An accurate definition of tumor position is the fundamental first step in planning a proper surgical treatment. Likewise, a generalized treatment policy for CPs is not valid nowadays. CP heterogeneity regarding tumor location and adhesion to adjacent structures support a tailored treatment based on a careful preoperative MRI assessment of topography and CP-brain relationships. CP topography and the pattern of CP-hypothalamus adhesions expected to be found during the surgical procedure can be reliably predicted with conventional MRI studies in most cases. The highest risk of hypothalamic injury during surgical removal is associated with tumors originated within the TVF itself (infundibulo-tuberal or not-strictly intraventricular CPs) or in suprasellar lesions that have eventually invaded the 3V (secondary-intraventricular CPs). These two CP categories are characterized by a direct contact between the tumor tissue and the hypothalamus without any intervening meningeal layer to be used as a safe dissection plane. In these cases, in which the hypothalamus is usually positioned around the mid-third or central region of the tumor and the pituitary stalk has an amputated appearance on preoperative MRI, an incomplete tumor removal is strongly recommended to avoid iatrogenic hypothalamic injury.


We especially thank Crystal Smith and Liliya Gusakova, reference librarians at the National Library of Medicine, NIH (Bethesda, MD), for their kind assistance during the process of searching and retrieving articles and monographs used in this study. We are indebted to Bill Landis and all the staff of the Manuscripts and Archives Department of the Sterling Memorial Library at Yale University (New Haven, CT) for their kind assistance in accessing the Cushing’s Brain Tumor Registry. We are also grateful to Melissa Grafe, librarian at the Medical History Library at Yale University (New Haven, CT) and Jack Eckert and the staff at the Francis Countway Medical Library at Harvard Medical School (Boston, MA) for their invaluable help in obtaining some of the original research used for this study. Finally, we are grateful to George Hamilton for his critical review of the language and style of the manuscript.

Author Contributions

Conception and design: Prieto and Pascual. Acquisition of data: Prieto and Pascual. Drafting the article: Prieto and Pascual. Critically revising the article: Prieto and Pascual.


This project did not obtain any financial support from a sponsor or research grant.

Competing Interests

The authors have declared that no competing interests exist.


  1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012; 14: v1-v49. [CrossRef]
  2. Yang P, Wang Y, Peng X, You G, Zhang W, Yan W, et al. Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution. J Neuro Oncol. 2013; 113: 259-266. [CrossRef]
  3. Weller M, Van Den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017; 18: e315-e329. [CrossRef]
  4. Herholz K. Brain tumors: an update on clinical PET research in gliomas. Semin Nucl Med. 2017; 47: 5-17. [CrossRef]
  5. Galldiks N. Neuroimaging in patients with high-grade gliomas. Q J Nucl Med Mol Imaging. 2018. [CrossRef]
  6. Volz L, Kocher M, Lohmann P, Shah N, Fink G, Galldiks N. Functional magnetic resonance imaging in glioma patients: from clinical applications to future perspectives. Q J Nucl Med Mol Imaging. 2018. [CrossRef]
  7. Schillaci O, Filippi L, Manni C, Santoni R. Single-photon emission computed tomography/computed tomography in brain tumors. Semin Nucl Med. 2007; 37: 34-47. [CrossRef]
  8. Spence AM, Mankoff DA, Muzi M. Positron emission tomography imaging of brain tumors. Neuroimaging Clin. 2003; 13: 717-739. [CrossRef]
  9. Heiss W-D, Raab P, Lanfermann H. Multimodality assessment of brain tumors and tumor recurrence.J Nucl Med. 2011; 52: 1585. [CrossRef]
  10. Herholz K, Langen K-J, Schiepers C, Mountz JM. Brain tumors. Semin Nucl Med. 2012; 42: 356-370. [CrossRef]
  11. Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016; 18: 1199-1208. [CrossRef]
  12. Assimakopoulos A, Polyzoidis K, Sioka C. Positron emission tomography imaging in gliomas. Neuroimmunol Neuroinflammation. 2014; 1; 107-114. [CrossRef]
  13. Heiss WD. Positron emission tomography imaging in gliomas: applications in clinical diagnosis, for assessment of prognosis and of treatment effects, and for detection of recurrences. Eur J Neurol. 2017; 24: e1255-e1270. [CrossRef]
  14. Verger A, Langen K-J. PET Imaging in Glioblastoma: Use in Clinical Practice. Glioblastoma [Internet]: Codon Publications. 2017.
  15. Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps Ma, Ido T, et al. The [18F] fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979; 44: 127-137. [CrossRef]
  16. Bergström M, Lundqvist H, Ericson K, Lilja A, Johnström P, Långström B, et al. Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol. 1987; 28: 225-229.
  17. Miyagawa T, Oku T, Uehara H, Desai R, Beattie B, Tjuvajev J, et al. “Facilitated” amino acid transport is upregulated in brain tumors. J Cerebr Blood F Met. 1998; 18: 500-509. [CrossRef]
  18. Becherer A, Karanikas G, Szabó M, Zettinig G, Asenbaum S, Marosi C, et al. Brain tumour imaging with PET: a comparison between [18 F] fluorodopa and [11 C] methionine. Eur J Nucl Med Mol I. 2003; 30: 1561-1567. [CrossRef]
  19. Weber WA, Wester H-J, Grosu AL, Herz M, Dzewas B, Feldmann H-J, et al. O-(2-[18 F] fluoroethyl)-L-tyrosine and L-[methyl-11 C] methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med. 2000; 27: 542-549. [CrossRef]
  20. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. The J Nucl Med. 2002; 43: 1210.
  21. Shields AF, Grierson JR, Dohmen BM, Machulla H-J, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18] FLT and positron emission tomography. Nat Med. 1998; 4: 1334. [CrossRef]
  22. Muzi M, Spence AM, O'Sullivan F, Mankoff DA, Wells JM, Grierson JR, et al. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas. J Nucl Med. 2006; 47: 1612-1621.
  23. Herholz K. Brain Tumors: An Update on Clinical PET Research in Gliomas. Semin Nucl Med. 2017; 47: 5-17. [CrossRef]
  24. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorncrews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998; 4: 1334. [CrossRef]
  25. Pietrzyk U, Herholz K, Heiss W. Three-dimensional alignment of functional and morphological tomograms. J Cmput Assist Tomo. 1990; 14: 51-59.
  26. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta neuropathol. 2007; 114: 97-109. [CrossRef]
  27. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131: 803-820. [CrossRef]
  28. Paulus W, Peiffer J. Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer. 1989; 64: 442-447. [CrossRef]
  29. Patronas N, Di Chiro G, Brooks R, DeLaPaz R, Kornblith P, Smith B, et al. Work in progress:[18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology. 1982; 144: 885-889. [CrossRef]
  30. Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995; 195: 47-52. [CrossRef]
  31. Spence AM, Muzi M, Mankoff DA, O'Sullivan SF. ^ sup 18^ F-FDG PET of Gliomas at Delayed Intervals: Improved Distinction Between Tumor and Normal Gray Matter. J Nucl Med. 2004; 45: 1653.
  32. Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology. 1982; 32: 1323. [CrossRef]
  33. Herholz K, Pietrzyk U, Voges J, Schröder R, Halber M, Treuer H, et al. Correlation of glucose consumption and tumor cell density in astrocytomas: a stereotactic PET study. J neurosurg. 1993; 79: 853-858. [CrossRef]
  34. Patronas NJ, Chiro GD, Kufta C, Bairamian D, Kornblith PL, Simon R, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg. 1985; 62: 816-822. [CrossRef]
  35. Hölzer T, Herholz K, Jeske J, Heiss W-D. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Cmput Assist Tomo. 1993; 17: 681-687. [CrossRef]
  36. Wray R, Solnes L, Mena E, Meoded A, Subramaniam RM. 18F-Flourodeoxy-glucose PET/computed tomography in brain tumors: value to patient management and survival outcomes. PET Clinics. 2015; 10: 423-430. [CrossRef]
  37. Levivier M, Goldman S, Pirotte B, Brucher J-M, Balériaux D, Luxen A, et al. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F] fluorodeoxyglucose. J Neurosurg. 1995; 82: 445-452. [CrossRef]
  38. Herholz K, Herscovitch P, Heiss W-D, Heiss W-D. NeuroPET: Positron Emission Tomography in Neuroscience and Clinical Neurology; 11 Tables: Springer Science & Business Media; 2004. [CrossRef]
  39. Ullrich RT, Kracht LW, Jacobs AH. Neuroimaging in patients with gliomas. Semin Neurol. 2008; 28: 484-494. [CrossRef]
  40. Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016; 18: 1199-1208. [CrossRef]
  41. Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, et al. Methyl-[11 C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol I. 2003; 30: 868-873. [CrossRef]
  42. Herholz K, Hölzer T, Bauer B, Schröder R, Voges J, Ernestus R, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998; 50: 1316-1322. [CrossRef]
  43. Chung J-K, Kim Y, Kim S-k, Lee Y, Paek S, Yeo J, et al. Usefulness of 11 C-methionine PET in the evaluation of brain lesions that are hypo-or isometabolic on 18 F-FDG PET. Eur J Nucl Med Mol I. 2002; 29: 176-182. [CrossRef]
  44. Kuwert T, Morgenroth C, Woesler B, Matheja P, Palkovic S, Vollet B, et al. Uptake of iodine-123-α-methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med. 1996; 23: 1345-1353. [CrossRef]
  45. Bergström M, Collins VP, Ehrin E, Ericson K, Eriksson L, Greitz T, et al. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga] EDTA,[11C] glucose, and [11C] methionine. J Cmput Assist Tomo. 1983; 7: 1062-1066. [CrossRef]
  46. Nuutinen J, Sonninen P, Lehikoinen P, Sutinen E, Valavaara R, Eronen E, et al. Radiotherapy treatment planning and long-term follow-up with [11C] methionine PET in patients with low-grade astrocytoma. International J Radiat Oncol Biol Phys. 2000; 48: 43-52. [CrossRef]
  47. Mineura K, Sasajima T, Kowada M, Uesaka Y, Shishido F. Innovative approach in the diagnosis of gliomatosis cerebri using carbon-11-L-methionine positron emission tomography. J Nucl Med: official publication, Soc Nucl Med. 1991; 32: 726-728.
  48. Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC. 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med. 2012; 53: 1709. [CrossRef]
  49. Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, et al. Value of 11 C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol I. 2013; 40: 615-635. [CrossRef]
  50. Suchorska B, Albert N, Bauer E, Tonn J, Galldiks N. The role of amino acid PET in the light of the new WHO classification 2016 for brain tumors. Q J Nucl Med Mol Imaging. 2018. [CrossRef]
  51. Näslund O, Smits A, Förander P, Laesser M, Bartek J, Gempt J, et al. Amino acid tracers in PET imaging of diffuse low-grade gliomas: a systematic review of preoperative applications. Acta Neurochir. 2018;1-10. [CrossRef]
  52. Derlon J-M, Petit-Taboué M-C, Chapon F, Beaudouin V, Noël M-H, Creveuil C, et al. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. Neurosurgery. 1997; 40: 276-287. [CrossRef]
  53. Kato T, Shinoda J, Oka N, Miwa K, Nakayama N, Yano H, et al. Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity. Am J Neuroradiol. 2008; 29: 1867-1871. [CrossRef]
  54. Galldiks N, Langen K-J, Pope WB. From the clinician's point of view-What is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol. 2015; 17: 1434-1444. [CrossRef]
  55. Villani V, Carapella CM, Chiaravalloti A, Terrenato I, Piludu F, Vidiri A, et al. The Role of PET [18F]FDOPA in Evaluating Low-grade Glioma. Anticancer Res. 2015; 35: 5117-5122.
  56. Dadone-Montaudie B, Ambrosetti D, Dufour M, Darcourt J, Almairac F, Coyne J, et al. [18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression. 2017; 12: e0184625.
  57. Gempt J, Bette S, Ryang Y-M, Buchmann N, Peschke P, Pyka T, et al. 18F-fluoro-ethyl-tyrosine positron emission tomography for grading and estimation of prognosis in patients with intracranial gliomas. Eur J Radiol. 2015; 84: 955-962. [CrossRef]
  58. Sweeney R, Polat B, Samnick S, Reiners C, Flentje M, Verburg FA. O-(2-[18 F] fluoroethyl)-l-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy. Ann Nucl Med. 2014; 28: 154-162. [CrossRef]
  59. Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S, et al. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology. 2015; 84: 710-719. [CrossRef]
  60. Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, et al. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol. 2013; 15:341-351. [CrossRef]
  61. Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Müller H-W, et al. O-(2-[18F] fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005; 128: 678-687. [CrossRef]
  62. Floeth FW, Pauleit D, Wittsack H-J, Langen KJ, Reifenberger G, Hamacher K, et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F] fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg. 2005; 102: 318-327. [CrossRef]
  63. Stadlbauer A, Prante O, Nimsky C, Salomonowitz E, Buchfelder M, Kuwert T, et al. Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2-18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging. J Nucl Med. 2008; 49: 721-729. [CrossRef]
  64. Albert NL, Winkelmann I, Suchorska B, Wenter V, Schmid-Tannwald C, Mille E, et al. Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans. Eur J Nucl Med Mol I. 2016; 43: 1105-1114. [CrossRef]
  65. Calcagni ML, Galli G, Giordano A, Taralli S, Anile C, Niesen A, et al. Dynamic O-(2-[18F] fluoroethyl)-L-tyrosine (F-18 FET) PET for glioma grading: assessment of individual probability of malignancy. Clin Nucl Med. 2011; 36: 841-847. [CrossRef]
  66. Pyka T, Gempt J, Ringel F, Hüttinger S, van Marwick S, Nekolla S, et al. Prediction of glioma recurrence using dynamic 18F-fluoroethyltyrosine PET. Am J Neuroradiol. 2014; 35: 1924-1929. [CrossRef]
  67. Lohmann P, Herzog H, Kops ER, Stoffels G, Judov N, Filss C, et al. Dual-time-point O-(2-[18F] fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas. Eur Radiol. 2015; 25: 3017-3024. [CrossRef]
  68. Niyazi M, Jansen N, Ganswindt U, Schwarz SB, Geisler J, Schnell O, et al. Re-irradiation in recurrent malignant glioma: prognostic value of [18 F] FET–PET. J Neuro-oncol. 2012; 110: 389-395. [CrossRef]
  69. Jansen NL, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, et al. Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med. 2014; jnumed. 113.122333.
  70. Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, et al. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro-oncol 2015; 17: 1293-1300. [CrossRef]
  71. Thon N, Kunz M, Lemke L, Jansen NL, Eigenbrod S, Kreth S, et al. Dynamic 18 F‐FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. IntJ Cancer. 2015; 136: 2132-2145. [CrossRef]
  72. Bashir A, Brennum J, Broholm H, Law I. The diagnostic accuracy of detecting malignant transformation of low-grade glioma using O-(2-[18F] fluoroethyl)-l-tyrosine positron emission tomography: a retrospective study. J Neurosurg. 2018: 1-14. [CrossRef]
  73. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, et al. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med. 2010; 51: 1532. [CrossRef]
  74. Janvier L, Olivier P, Blonski M, Morel O, Vignaud J-M, Karcher G, et al. Correlation of SUV-derived indices with tumoral aggressiveness of gliomas in static 18F-FDOPA PET: use in clinical practice. Clin Nucl Med. 2015; 40: e429-e435. [CrossRef]
  75. Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, et al. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro-oncol. 2013; 16: 603-609. [CrossRef]
  76. Karunanithi S, Sharma P, Kumar A, Gupta DK, Khangembam BC, Ballal S, et al. Can 18F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study. Eur J Radiol. 2014; 83: 219-225. [CrossRef]
  77. Patel CB, Fazzari E, Chakhoyan A, Yao J, Raymond C, Nguyen H, et al. 18 F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. J Neuro Oncol. 2018: 1-11.
  78. Villani V, Carapella CM, Chiaravalloti A, Terrenato I, Piludu F, Vidiri A, et al. The role of PET [18F] FDOPA in evaluating low-grade glioma. Anticancer Res. 2015; 35: 5117-5122.
  79. Lapa C, Linsenmann T, Monoranu CM, Samnick S, Buck AK, Bluemel C, et al. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients. J Nucl Med. 2014; 55: 1611-1616. [CrossRef]
  80. Nikaki A, Angelidis G, Efthimiadou R, Tsougos I, Valotassiou V, Fountas K, et al. 18 F-fluorothymidine PET imaging in gliomas: an update. Ann Nucl Med. 2017; 31: 495-505. [CrossRef]
  81. Ullrich R, Backes H, Li H, Kracht L, Miletic H, Kesper K, et al. Glioma proliferation as assessed by 3 ‘-fluoro-3’-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res. 2008; 14: 2049-2055. [CrossRef]
  82. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005; 46: 945-952.
  83. Collet S, Valable S, Constans J, Lechapt-Zalcman E, Roussel S, Delcroix N, et al. [18F]-fluoro-l-thymidine PET and advanced MRI for preoperative grading of gliomas. NeuroImage: Clinical. 2015 ;8: 448-454. [CrossRef]
  84. Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, et al. 11 C-methionine (MET) and 18 F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol I. 2008; 35: 2009-2017. [CrossRef]
  85. Tripathi M, Sharma R, D'souza M, Jaimini A, Panwar P, Varshney R, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med. 2009; 34: 878-883. [CrossRef]
  86. Idema A, Hoffmann AL, Boogaarts HD, Troost E, Wesseling P, Heerschap A, et al. 30-Deoxy-30-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients. J Nucl Med. 2012; 53: 1904-1910. [CrossRef]
  87. DeLaPaz R, Patronas NJ, Brooks RA, Smith BH, Kornblith PL, Milam H, et al. Positron emission tomographic study of suppression of gray-matter glucose utilization by brain tumors. Am J Neuroradiol. 1983; 4: 826-829.
  88. Wunderlich G, Knorr U, Herzog H, Kiwit JC, Freund H-J, Seitz RJ. Precentral glioma location determines the displacement of cortical hand representation. Neurosurgery. 1998; 42: 18-27. [CrossRef]
  89. Thiel A, Herholz K, Koyuncu A, Ghaemi M, Kracht LW, Habedank B, et al. Plasticity of language networks in patients with brain tumors: A PET activation study. AnnNeurol. 2001; 50: 620-629. [CrossRef]
  90. Keunen O, Taxt T, Grüner R, Lund-Johansen M, Tonn J-C, Pavlin T, et al. Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. Adv Drug Deliver Rev. 2014; 76: 98-115. [CrossRef]
  91. Brock C, Young H, O'Reilly S, Matthews J, Osman S, Evans H, et al. Early evaluation of tumour metabolic response using [18 F] fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. British J Cancer. 2000; 82: 608. [CrossRef]
  92. Glantz MJ, Hoffman JM, Coleman RE, Friedman AH, Hanson MW, Burger PC, et al. Identification of early recurrence of primary central nervous system tumors by [18F] fluorodeoxyglucose positron emission tomography. Ann Neurol. 1991; 29: 347-355. [CrossRef]
  93. Charnley N, West CM, Barnett CM, Brock C, Bydder GM, Glaser M, et al. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys. 2006; 66: 331-338. [CrossRef]
  94. Sarkaria JN, Galanis E, Wu W, Peller PJ, Giannini C, Brown PD, et al. North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011; 81: 468-475. [CrossRef]
  95. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? Am J Neuroradiol. 1998; 19: 407-413.
  96. Tanaka Y, Nariai T, Momose T, Aoyagi M, Maehara T, Tomori T, et al. Glioma surgery using a multimodal navigation system with integrated metabolic images. J Neurosurg. 2009; 110: 163-172. [CrossRef]
  97. Grosu A-L, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M, et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy.Int J Radiat Oncol Biol Phys. 2005; 63: 64-74. [CrossRef]
  98. Weber DC, Zilli T, Buchegger F, Casanova N, Haller G, Rouzaud M, et al. [(18) F] Fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol. 2008; 3: 44. [CrossRef]
  99. Vees H, Senthamizhchelvan S, Miralbell R, Weber DC, Ratib O, Zaidi H. Assessment of various strategies for 18 F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol I. 2009; 36: 182-193. [CrossRef]
  100. Nariai T, Tanaka Y, Wakimoto H, Aoyagi M, Tamaki M, Ishiwata K, et al. Usefulness of l-[methyl-11C] methionine—positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg. 2005; 103: 498-507. [CrossRef]
  101. Thiel A, Pietrzyk U, Sturm V, Herholz K, Hövels M, Schröder R. Enhanced accuracy in differential diagnosis of radiation necrosis by positron emission tomography-magnetic resonance imaging coregistration: technical case report. Neurosurgery. 2000; 46: 232-234. [CrossRef]
  102. Tsuyuguchi N, Takami T, Sunada I, Iwai Y, Yamanaka K, Tanaka K, et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery—In malignant glioma—. Ann Nucl Med. 2004; 18: 291-296. [CrossRef]
  103. Terakawa Y, Tsuyuguchi N, Iwai Y, Yamanaka K, Higashiyama S, Takami T, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008. [CrossRef]
  104. Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, et al. Direct comparison of 18 F-FDG and 11 C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol I. 2005; 32: 39-51. [CrossRef]
  105. Yamane T, Sakamoto S, Senda M. Clinical impact of 11 C-methionine PET on expected management of patients with brain neoplasm. Eur J Nucl Med Mol I. 2010; 37: 685-690. [CrossRef]
  106. Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH, Heiss WD, et al. Use of 11 C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol I. 2006; 33: 516-524. [CrossRef]
  107. Wyss M, Hofer S, Bruehlmeier M, Hefti M, Uhlmann C, Bärtschi E, et al. Early metabolic responses in temozolomide treated low-grade glioma patients. J Neuro Oncol. 2009; 95: 87-93. [CrossRef]
  108. Galldiks N, Kracht LW, Burghaus L, Ullrich RT, Backes H, Brunn A, et al. Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging. 2010; 9: 7 290.2010. 00002.
  109. Ono T, Sasajima T, Doi Y, Oka S, Ono M, Kanagawa M, et al. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma. Nucl Med Biol. 2015; 42: 598-607. [CrossRef]
  110. Mehrkens J, Pöpperl G, Rachinger W, Herms J, Seelos K, Tatsch K, et al. The positive predictive value of O-(2-[18 F] fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neuro Oncol. 2008; 88: 27-35. [CrossRef]
  111. Rachinger W, Goetz C, Pöpperl G, Gildehaus FJ, Kreth FW, Holtmannspötter M, et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery. 2005; 57: 505-511. [CrossRef]
  112. Galldiks N, Langen KJ, Holy R, Pinkawa M, Stoffels G, Nolte KW, et al. Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-18F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI. J Nucl Med. 2012; 53: 1048-1057. [CrossRef]
  113. Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G, et al. Prognostic Value of Early [F]Fluoroethyltyrosine Positron Emission Tomography After Radiochemotherapy in Glioblastoma Multiforme. Int J Radiat Oncol Biol Phys. 2011; 80: 176-184. [CrossRef]
  114. Galldiks N, Rapp M, Stoffels G, Fink GR, Shah NJ, Coenen HH, et al. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol I. 2013; 40: 22-33. [CrossRef]
  115. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, et al. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res. 2014; 20: 3550-3559. [CrossRef]
  116. Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging. 2015; 42: 685-695. [CrossRef]
  117. Heinzel A, Müller D, Langen KJ, Blaum M, Verburg FA, Mottaghy FM, et al. The Use of O-(2-18F-Fluoroethyl)-l-Tyrosine PET for Treatment Management of Bevacizumab and Irinotecan in Patients with Recurrent High-Grade Glioma: A Cost-Effectiveness Analysis. J Nucl Med. 2013; 54: 1217-1222. [CrossRef]
  118. Jansen NL, Suchorska B, Schwarz SB, Eigenbrod S, Lutz J, Graute V, et al. [18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma. Mol Imaging. 2013; 12: 137-147. [CrossRef]
  119. Niyazi M, Jansen NL, Rottler M, Ganswindt U, Belka C. Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients. Radiat Oncol. 2014; 9: 299. [CrossRef]
  120. Franceschi E, Bartolotti M, Brandes AA. Bevacizumab in recurrent glioblastoma: open issues. Future Oncol. 2015; 11: 2655-2665. [CrossRef]
  121. Galldiks N, Kocher M, Langen KJ. Pseudoprogression after glioma therapy: an update. Expert Rev Neurother. 2017; 17. [CrossRef]
  122. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clinl Oncol. 2007; 25: 4714-4721. [CrossRef]
  123. Wardak M, Schiepers C, Dahlbom M, Cloughesy T, Chen W, Satyamurthy N, et al. Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin Cancer Res. 2011; 17: 6553-6562. [CrossRef]
  124. Corroyer-Dulmont, Aurelien, Jacobs, Andreas H. Detection of glioblastoma response to temozolomide combined with;bevacizumab based on mu MRI and mu PET imaging reveals;[F-18]-fluoro-L-thymidine as an early and robust predictive marker for;treatment efficacy. Neuro Oncol. 2013; 15: 41-56. [CrossRef]
  125. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, et al. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012; 53: 29-36. [CrossRef]
  126. Wardak M, Schiepers C, Cloughesy TF, Dahlbom M, Phelps ME, Huang SC. 18 F-FLT    and 18 F-FDOPA PET kinetics in recurrent brain tumors. Eur J Nucl Med & Molecular Imaging. 2014; 41: 1199-1209. [CrossRef]
  127. Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, et al. Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro-Oncol. 2009; 11: 861. [CrossRef]
  128. Jacobs A, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L, et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet. 2001; 358: 727-729. [CrossRef]
  129. Vredenburgh JJ, Desjardins A, Nd HJ, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25: 4722-4729. [CrossRef]
  130. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol. 2010; 28: 1963. [CrossRef]
  131. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008; 113: 405-410. [CrossRef]
  132. Hutterer M, Nowosielski M, Putzer D, Waitz D, Tinkhauser G, Kostron H, et al. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. J Nucl Med. 2011; 52: 856-864. [CrossRef]
  133. Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, et al. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med. 2010; 51: 720-727. [CrossRef]
  134. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, et al. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res. 2014; 20: 3550-3559. [CrossRef]
  135. De Witte O, Levivier M, Violon P, Salmon I, Damhaut P, Wikler D, Jr., et al. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery. 1996; 39: 470-476.
  136. Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med. 2000; 41: 1861-1867.
  137. Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol. 1988; 150: 189-197. [CrossRef]
  138. Levivier M, Becerra A, De WO, Brotchi J, Goldman S. Radiation necrosis or recurrence. J Neurosurg. 1996; 84: 148.
  139. Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer. 2001; 96: 191-197. [CrossRef]
  140. Herholz K, Langen KJ, Schiepers C, Mountz JM. Brain tumors. Semin Nucl Med. 2012; 42: 356-370. [CrossRef]
  141. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med. 1997; 38: 280-287.
  142. Takenaka S, Asano Y, Shinoda J, Nomura Y, Yonezawa S, Miwa K, et al. Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis. Neurologia medico-chirurgica. 2014; 54: 280-289. [CrossRef]
  143. Minamimoto R, Saginoya T, Kondo C, Tomura N, Ito K, Matsuo Y, et al. Differentiation of Brain Tumor Recurrence from Post-Radiotherapy Necrosis with 11C-Methionine PET: Visual Assessment versus Quantitative Assessment. PloS one. 2015; 10: e0132515. [CrossRef]
  144. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol. 2006; 27: 1432-1437.
  145. Pöpperl G, Götz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med & Mol Imaging. 2004; 31: 1464-1470. [CrossRef]
  146. Laukamp KR, Lindemann F, Weckesser M, Hesselmann V, Ligges S, Wolfer J, et al. Multimodal Imaging of Patients With Gliomas Confirms (11)C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After Therapy. Mol Imaging. 2017; 16: 1536012116687651. [CrossRef]
  147. Chen W. Clinical Applications of PET in Brain Tumors. J Nucl Med. 2007; 48: 1468. [CrossRef]
  148. Dunet V, Rossier C, Buck A, Stupp R, Prior JO. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med. 2012; 53: 207-214. [CrossRef]
  149. Pyka T, Hiob D, Preibisch C, Gempt J, Wiestler B, Schlegel J, et al. Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI. Eur J Radiol. 2018; 103: 32-37. [CrossRef]
  150. Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, et al. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol. 2009; 71: 242-248. [CrossRef]
  151. Cicone F, Filss CP, Minniti G, Rossi-Espagnet C, Papa A, Scaringi C, et al. Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI. Eur J Nucl Med Mol Imaging. 2015; 42: 905-915. [CrossRef]
  152. Karunanithi S, Sharma P, Kumar A, Khangembam BC, Bandopadhyaya GP, Kumar R, et al. 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2013; 40: 1025-1035. [CrossRef]
  153. Li Z, Yu Y, Zhang H, Xu G, Chen L. A meta-analysis comparing 18F-FLT PET with 18F-FDG PET for assessment of brain tumor recurrence. Nucl Med Communicat. 2015; 36: 695-701. [CrossRef]
  154. Zhao F, Cui Y, Li M, Fu Z, Chen Z, Kong L, et al. Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas. Nucl Med Biol. 2014; 41: 710-715. [CrossRef]
  155. Spence AM, Muzi M, Link JM, O'Sullivan F, Eary JF, Hoffman JM, et al. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies. Mol Imaging Biol. 2009; 11: 343-355. [CrossRef]
  156. Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB, Becker M, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med. 2008; 14: 459-465. [CrossRef]
  157. Schlemmer HP, Pichler BJ, Schmand M, Burbar Z, Michel C, Ladebeck R, et al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology. 2008; 248: 1028-1035. [CrossRef]
  158. Heiss WD. The potential of PET/MR for brain imaging. Eur J Nucl Med Mol Imaging. 2009; 36 Suppl 1: S105-112. [CrossRef]
  159. Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med. 2010; 51: 1198-1205. [CrossRef]
  160. Catana C, Drzezga A, Heiss WD, Rosen BR. PET/MRI for neurologic applications. Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine. 2012; 53: 1916-1925. [CrossRef]
  161. Shin HW, Jewells V, Sheikh A, Zhang J, Zhu H, An H, et al. Initial experience in hybrid PET-MRI for evaluation of refractory focal onset epilepsy. Seizure Eur J Epilepsy. 2015; 31: 1-4. [CrossRef]
  162. Verger A, Filss CP, Lohmann P, Stoffels G, Sabel M, Wittsack HJ, et al. Comparison of O-(2-(18)F-Fluoroethyl)-L-Tyrosine Positron Emission Tomography and Perfusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Patients with Progressive and Recurrent Glioma: A Hybrid Positron Emission Tomography/Magnetic Resonance Study. World Neurosurg. 2018; 113: e727-e737. [CrossRef]
  163. Fink JR, Muzi M, Peck M, Krohn KA. Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging. J Nucl Med. 2015; 56: 1554-1561. [CrossRef]
  164. Marner L, Henriksen OM, Lundemann M, Larsen VA, Law I. Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective. Clin Translational imaging. 2017; 5: 135-149. [CrossRef]
  165. Broski SM, Goenka AH, Kemp BJ, Johnson GB. Clinical PET/MRI: 2018 Update. AJR Am J Roentgenol. 2018; 211: 295-313. [CrossRef]
  166. Chiang GC, Kovanlikaya I, Choi C, Ramakrishna R, Magge R, Shungu DC. Magnetic Resonance Spectroscopy, Positron Emission Tomography and Radiogenomics-Relevance to Glioma. Front Neurol. 2018; 9: 33. [CrossRef]
  167. la Fougere C, Suchorska B, Bartenstein P, Kreth FW, Tonn JC. Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol. 2011; 13: 806-819. [CrossRef]
  168. Preuss M, Werner P, Barthel H, Nestler U, Christiansen H, Hirsch FW, et al. Integrated PET/MRI for planning navigated biopsies in pediatric brain tumors. Child's nervous system. 2014; 30: 1399-1403. [CrossRef]
  169. Burhan AM, Marlatt NM, Palaniyappan L, Anazodo UC, Prato FS. Role of Hybrid Brain Imaging in Neuropsychiatric Disorders. Diagnostics (Basel, Switzerland). 2015; 5: 577-614. [CrossRef]
  170. Bisdas S, La Fougere C, Ernemann U. Hybrid MR-PET in Neuroimaging. Clin Neuroradiol. 2015; 25 Suppl 2: 275-281. [CrossRef]
  171. Werner P, Barthel H, Drzezga A, Sabri O. Current status and future role of brain PET/MRI in clinical and research settings. Eur J Nucl Med Mol Imaging. 2015; 42: 512-526. [CrossRef]
  172. Sacconi B, Raad RA, Lee J, Fine H, Kondziolka D, Golfinos JG, et al. Concurrent functional and metabolic assessment of brain tumors using hybrid PET/MR imaging. J Neurooncol. 2016; 127: 287-293. [CrossRef]
  173. Filss CP, Galldiks N, Stoffels G, Sabel M, Wittsack HJ, Turowski B, et al. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. J Nucl Med. 2014; 55: 540-545. [CrossRef]
  174. Jena A, Taneja S. Multiparametric Evaluation in Differentiating Glioma Recurrence from Treatment-Induced Necrosis Using Simultaneous (18)F-FDG-PET/MRI: A Single-Institution Retrospective Study. 2017; 38: 899-907.
  175. Sogani SK, Jena A, Taneja S, Gambhir A, Mishra AK, D'Souza MM, et al. Potential for differentiation of glioma recurrence from radionecrosis using integrated 18F-fluoroethyl-L-tyrosine (FET) positron emission tomography/magnetic resonance imaging: A prospective evaluation. 2017.
  176. Puttick S, Bell C, Dowson N, Rose S, Fay M. PET, MRI, and simultaneous PET/MRI in the development of diagnostic and therapeutic strategies for glioma. Drug Discov Today. 2015; 20: 306-317. [CrossRef]
  177. Neuner I, Kaffanke JB, Langen KJ, Kops ER, Tellmann L, Stoffels G, et al. Multimodal imaging utilising integrated MR-PET for human brain tumour assessment. Eur Radiol. 2012; 22: 2568-2580. [CrossRef]
  178. Ertl-Wagner B, Ingrisch M, Niyazi M, Schnell O, Jansen N, Forster S, et al. [PET-MR in patients with glioblastoma multiforme]. Der Radiologe. 2013; 53: 682-690. [CrossRef]
  179. Jeong JW, Juhasz C, Mittal S, Bosnyak E, Kamson DO, Barger GR, et al. Multi-modal imaging of tumor cellularity and Tryptophan metabolism in human Gliomas. Cancer imaging. 2015;15: 10. [CrossRef]
  180. Morana G, Piccardo A, Puntoni M, Nozza P, Cama A, Raso A, et al. Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study. Neuro Oncol. 2015; 17: 1637-1647. [CrossRef]
  181. da Silva NA, Lohmann P, Fairney J, Magill AW, Oros Peusquens AM, Choi CH, et al. Hybrid MR-PET of brain tumours using amino acid PET and chemical exchange saturation transfer MRI. Eur J Nucl Med Mol Imaging. 2018; 45: 1031-1040. [CrossRef]